{
  "questions": [
    {
      "id": "63f03006f36125a426000018",
      "type": "summary",
      "body": "What were the results of the DESTINY-Breast04 Trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
          "text": "CONCLUSIONS\nIn this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.",
          "offsetInBeginSection": 2191,
          "offsetInEndSection": 2414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
          "text": "DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd).",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31022475",
          "text": "After evaluating the results of these 6 studies, none of the SNPs was significantly associated with ONJ.",
          "offsetInBeginSection": 732,
          "offsetInEndSection": 836,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
          "text": "Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023880",
          "text": "using a validated scoring criterion.\n\n\nRESULTS\nOne hundred and seven studies met the inclusion criteria. The median quality score across studies was 1",
          "offsetInBeginSection": 1053,
          "offsetInEndSection": 1203,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "In total, 45 samples were positive with breath testing and the number of positives with established forensic methods was 46.",
          "offsetInBeginSection": 1411,
          "offsetInEndSection": 1535,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33023880",
          "text": "and temperature selected in over 50% of the studies. Malaria incidence (47%) and prevalence (35%) were the most commonly mapped outcomes, with Bayesia",
          "offsetInBeginSection": 1333,
          "offsetInEndSection": 1483,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
          "text": "In 54 of these cases (81%) the results regarding a positive or negative drug test result agreed and in 13 they disagreed.",
          "offsetInBeginSection": 884,
          "offsetInEndSection": 1005,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2748781",
          "text": "Yet like him, physicians must realize that the small successes they can achieve while contending against destiny are what count.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 262,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
          "text": "We report here the 30-day mortality and 6- and 12-month functional outcomes from the DESTINY trial.",
          "offsetInBeginSection": 177,
          "offsetInEndSection": 276,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/2748781",
        "http://www.ncbi.nlm.nih.gov/pubmed/35666611",
        "http://www.ncbi.nlm.nih.gov/pubmed/36386213",
        "http://www.ncbi.nlm.nih.gov/pubmed/17690310",
        "http://www.ncbi.nlm.nih.gov/pubmed/31022475",
        "http://www.ncbi.nlm.nih.gov/pubmed/31039047",
        "http://www.ncbi.nlm.nih.gov/pubmed/35665782",
        "http://www.ncbi.nlm.nih.gov/pubmed/33023880"
      ]
    },
    {
      "id": "641ad941690f196b5100003d",
      "type": "yesno",
      "body": "Are LOQ and LOD the same?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
          "text": "of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here about the LOD/LOQ ",
          "offsetInBeginSection": 988,
          "offsetInEndSection": 1138,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
          "text": "The results indicated that the estimated LODs and LOQs were not equivalent and could vary by a factor of 5 to 6 for the different methods.",
          "offsetInBeginSection": 488,
          "offsetInEndSection": 626,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
          "text": "Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29110333",
          "text": "precision, accuracy, and robustness. The LOD and LOQ obtained were 0.8 and 2.7\u00a0\u03bcg/mL, respectively. In addition, the method offers higher sensitivity ",
          "offsetInBeginSection": 518,
          "offsetInEndSection": 668,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15936163",
          "text": "nt (r) of 0.9999, calculated by least square method. The LOD and LOQ were 0.08 and 0.26 microg/mL, respectively. Based on the preliminary spectrophoto",
          "offsetInBeginSection": 632,
          "offsetInEndSection": 782,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29110333",
        "http://www.ncbi.nlm.nih.gov/pubmed/8013092",
        "http://www.ncbi.nlm.nih.gov/pubmed/20166602",
        "http://www.ncbi.nlm.nih.gov/pubmed/21603916",
        "http://www.ncbi.nlm.nih.gov/pubmed/15936163"
      ]
    },
    {
      "id": "642a029d57b1c7a315000011",
      "type": "summary",
      "body": "Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
          "text": "ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
          "text": "The eukaryotic histone acetylation cycle is composed of three classes of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of the most characterized of several protein domains that recognize acetyl-lysine (Kac) and effect downstream function, and histone deacetylases (HDACs) that catalyze the reverse reaction.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 402,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11112280",
          "text": "residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
          "text": "ther transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequenc",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
          "text": " A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural simil",
          "offsetInBeginSection": 108,
          "offsetInEndSection": 258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29261229",
          "text": "e family that regulates these processes by catalyzing the transfer of an acetyl moiety onto target proteins. Perturbations of cellular acetylation pro",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
          "text": ") are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine resi",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10790315",
          "text": "Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
          "text": "tisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency. Rtt109 is a particularly interesting example ",
          "offsetInBeginSection": 54,
          "offsetInEndSection": 204,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31818759",
          "text": "enzyme A (Ac-CoA) to lysine residues of substrate peptide, thus generating CoA molecule. Later, CoA, which acts as an initiator, can embrace its aptam",
          "offsetInBeginSection": 371,
          "offsetInEndSection": 521,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32157780",
        "http://www.ncbi.nlm.nih.gov/pubmed/31818759",
        "http://www.ncbi.nlm.nih.gov/pubmed/21057107",
        "http://www.ncbi.nlm.nih.gov/pubmed/12368900",
        "http://www.ncbi.nlm.nih.gov/pubmed/12624111",
        "http://www.ncbi.nlm.nih.gov/pubmed/32695779",
        "http://www.ncbi.nlm.nih.gov/pubmed/29261229",
        "http://www.ncbi.nlm.nih.gov/pubmed/10790315",
        "http://www.ncbi.nlm.nih.gov/pubmed/12391296",
        "http://www.ncbi.nlm.nih.gov/pubmed/11112280"
      ]
    },
    {
      "id": "6432fc0457b1c7a31500001f",
      "type": "factoid",
      "body": "Which gene is most frequently mutated in hereditary angioedema ?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
          "text": "he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
          "text": "), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 689,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27470642",
          "text": "Angioedema can be caused by C1-inhibitor deficiency (C1-INH-hereditary angioedema and C1-INH-acquired angioedema), mutations in coagulation factor XII (FXII-hereditary angioedema), and treatment with angiotensin-converting enzyme inhibitors (ACEI-acquired angioedema).",
          "offsetInBeginSection": 695,
          "offsetInEndSection": 963,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30044938",
          "text": "BACKGROUND\nHereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
          "text": "used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
          "text": "The fundamental cause of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor.",
          "offsetInBeginSection": 424,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
          "text": "childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedem",
          "offsetInBeginSection": 353,
          "offsetInEndSection": 503,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
          "text": "Genetic testing revealed a heterozygous nonsense mutation of the SERPING1 gene, and a diagnosis of hereditary angioedema was made.",
          "offsetInBeginSection": 520,
          "offsetInEndSection": 650,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
          "text": "utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27116602",
          "text": "d function of bradykinin. Alterations detected in at least one more gene (F12) are nowadays considered responsible for 25\u00a0% of cases of hereditary ang",
          "offsetInBeginSection": 539,
          "offsetInEndSection": 689,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36417927",
        "http://www.ncbi.nlm.nih.gov/pubmed/34065094",
        "http://www.ncbi.nlm.nih.gov/pubmed/33780405",
        "http://www.ncbi.nlm.nih.gov/pubmed/30146609",
        "http://www.ncbi.nlm.nih.gov/pubmed/24760113",
        "http://www.ncbi.nlm.nih.gov/pubmed/27116602",
        "http://www.ncbi.nlm.nih.gov/pubmed/33593719",
        "http://www.ncbi.nlm.nih.gov/pubmed/36203343",
        "http://www.ncbi.nlm.nih.gov/pubmed/27470642",
        "http://www.ncbi.nlm.nih.gov/pubmed/30044938"
      ]
    },
    {
      "id": "64178edb690f196b51000025",
      "type": "summary",
      "body": "What is casimersen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
          "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
          "text": "mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 377,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
          "text": "d the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Mu",
          "offsetInBeginSection": 185,
          "offsetInEndSection": 335,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1572,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
          "text": "These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19719780",
        "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089283"
      ]
    },
    {
      "id": "6402bf2b201352f04a000007",
      "type": "summary",
      "body": "What is the mechanism of action of tiragolumab?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": " (16\u00b72% [6\u00b77-25\u00b77]) in the placebo plus atezolizumab group had an objective response (p=0\u00b7031). Median progression-free survival was 5\u00b74 months (95% C",
          "offsetInBeginSection": 2161,
          "offsetInEndSection": 2311,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
          "text": "tion with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically signifi",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "INTERPRETATION\nTiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.",
          "offsetInBeginSection": 2991,
          "offsetInEndSection": 3259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
          "text": "BACKGROUND\nTargeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26292636",
          "text": "Tramadol is an analgesic that is used worldwide for pain, but its mechanisms of action have not been fully elucidated.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.",
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.",
          "offsetInBeginSection": 1406,
          "offsetInEndSection": 1627,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35292828",
          "text": "Our aim was to evaluate ex vivo the capacity of the combination of atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reactivate the immune response of tumor infiltrating lymphocytes (TILs) in MSS-CRC.",
          "offsetInBeginSection": 190,
          "offsetInEndSection": 398,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652612",
          "text": "Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35576957",
        "http://www.ncbi.nlm.nih.gov/pubmed/32576590",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652612",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/26292636",
        "http://www.ncbi.nlm.nih.gov/pubmed/35292828"
      ]
    },
    {
      "id": "641d8fd6690f196b51000041",
      "type": "list",
      "body": "What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34421896",
          "text": "Conclusions\nOur study highlighted the importance of mitophagy in MS and suggested the potential application of PINK1 and PARKIN as biomarkers to predict disease activity.",
          "offsetInBeginSection": 1039,
          "offsetInEndSection": 1209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
          "text": "This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.",
          "offsetInBeginSection": 549,
          "offsetInEndSection": 882,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
          "text": "th a sensitivity of 73.0% and a specificity of 75.8%.\n\n\nCONCLUSIONS\nsGFAP and sNfL are likely to be good biomarkers of disease activity and disability",
          "offsetInBeginSection": 1327,
          "offsetInEndSection": 1477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33019871",
          "text": "This article summarized the research progress in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD.",
          "offsetInBeginSection": 619,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
          "text": "toimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NM",
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
          "text": "Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
          "text": "ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1384,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31471502",
        "http://www.ncbi.nlm.nih.gov/pubmed/34421896",
        "http://www.ncbi.nlm.nih.gov/pubmed/36378751",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887254",
        "http://www.ncbi.nlm.nih.gov/pubmed/27049569",
        "http://www.ncbi.nlm.nih.gov/pubmed/25027264",
        "http://www.ncbi.nlm.nih.gov/pubmed/33019871"
      ]
    },
    {
      "id": "6429d5c557b1c7a315000006",
      "type": "list",
      "body": "What are the major thrombotic complications in patients with COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36289613",
          "text": "n has been associated with thrombotic complications, especially venous thromboembolism. Although arterial thrombotic complications are rarely seen in ",
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
          "text": "ne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli. The endothelial expression of angiotensin-converting enzyme-2 rec",
          "offsetInBeginSection": 794,
          "offsetInEndSection": 944,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113402",
          "text": "BACKGROUND\nThromboembolic events are common complications of COVID-19. Clinical study results on safety and efficacy of anticoagulation in COVID-19 ar",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
          "text": "These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.",
          "offsetInBeginSection": 94,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32586214",
          "text": "causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg,",
          "offsetInBeginSection": 1057,
          "offsetInEndSection": 1207,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
          "text": "Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines.",
          "offsetInBeginSection": 605,
          "offsetInEndSection": 816,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
          "text": "INTRODUCTION\nThrombosis and bleeding are recognized complications of the novel coronavirus infection (COVID-19), with a higher incidence described particularly in the critically ill.\n\n\nMETHODS\nA retrospective review of COVID-19 patients admitted to our intensive care units (ICU) between 1 January 2020 and 31 December 2020 was performed.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 338,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32551814",
          "text": "V-2). Coagulation dysfunction is a hallmark in patients with COVID-19. Fulminant thrombotic complications emerge as critical issues in patients with s",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
          "text": "Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.",
          "offsetInBeginSection": 89,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36113402",
        "http://www.ncbi.nlm.nih.gov/pubmed/33569525",
        "http://www.ncbi.nlm.nih.gov/pubmed/34271813",
        "http://www.ncbi.nlm.nih.gov/pubmed/34512059",
        "http://www.ncbi.nlm.nih.gov/pubmed/34884354",
        "http://www.ncbi.nlm.nih.gov/pubmed/35967591",
        "http://www.ncbi.nlm.nih.gov/pubmed/32586214",
        "http://www.ncbi.nlm.nih.gov/pubmed/32551814",
        "http://www.ncbi.nlm.nih.gov/pubmed/36289613"
      ]
    },
    {
      "id": "6433012b57b1c7a315000022",
      "type": "summary",
      "body": "What is Cinryze?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
          "text": "ted States: Berinert(\u00ae) for treating acute attacks and Cinryze(\u00ae) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con",
          "offsetInBeginSection": 745,
          "offsetInEndSection": 895,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20627701",
          "text": "Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
          "text": "Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze\u00ae) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "o long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with ecall",
          "offsetInBeginSection": 782,
          "offsetInEndSection": 932,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
          "text": "he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze\u2122), distributed by Lev Pharmaceuticals, was a",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 884,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "a blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "STUDY DESIGN AND METHODS\nThe analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates.",
          "offsetInBeginSection": 460,
          "offsetInEndSection": 605,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
          "text": "Additional bands in the plasma-derived products were \u03b11-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert).",
          "offsetInBeginSection": 1354,
          "offsetInEndSection": 1518,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
          "text": "ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with",
          "offsetInBeginSection": 776,
          "offsetInEndSection": 926,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.",
          "offsetInBeginSection": 1021,
          "offsetInEndSection": 1104,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23776358",
        "http://www.ncbi.nlm.nih.gov/pubmed/26756974",
        "http://www.ncbi.nlm.nih.gov/pubmed/21942916",
        "http://www.ncbi.nlm.nih.gov/pubmed/22282695",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
        "http://www.ncbi.nlm.nih.gov/pubmed/24805006",
        "http://www.ncbi.nlm.nih.gov/pubmed/20627701"
      ]
    },
    {
      "id": "64179337690f196b51000034",
      "type": "yesno",
      "body": "Do machine learning-based methods outperform statistical methods for survival analysis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
          "text": " and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia",
          "offsetInBeginSection": 568,
          "offsetInEndSection": 718,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12717015",
          "text": "It has been found that machine-learning methods outperform statistical methods and achieve an MCC of 0.11 when secondary structure information is used.",
          "offsetInBeginSection": 633,
          "offsetInEndSection": 784,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
          "text": "Despite their potential advantages over standard statistical methods, like their ability to model non-linear relationships and construct symbolic and interpretable models, their applications to survival analysis are at best rare, primarily because of the difficulty to appropriately handle censored data.",
          "offsetInBeginSection": 149,
          "offsetInEndSection": 453,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
          "text": "Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.",
          "offsetInBeginSection": 847,
          "offsetInEndSection": 1091,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409119",
          "text": "on constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concor",
          "offsetInBeginSection": 1858,
          "offsetInEndSection": 2008,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
          "text": "BACKGROUND\nMachine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 221,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825008",
          "text": "MLAs provided higher identification accuracy (30.8-100%) than distance- (15.1-97.4%) and tree-based methods (11.1-87.5%), with SMO performing the best among the machine learning classifiers.",
          "offsetInBeginSection": 1111,
          "offsetInEndSection": 1301,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
          "text": "CONCLUSION\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores for predicting 1-month, 3-month, and 12-month survival following liver transplantation.",
          "offsetInBeginSection": 2443,
          "offsetInEndSection": 2680,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36227551",
        "http://www.ncbi.nlm.nih.gov/pubmed/34862545",
        "http://www.ncbi.nlm.nih.gov/pubmed/11185421",
        "http://www.ncbi.nlm.nih.gov/pubmed/30825008",
        "http://www.ncbi.nlm.nih.gov/pubmed/34910160",
        "http://www.ncbi.nlm.nih.gov/pubmed/36028137",
        "http://www.ncbi.nlm.nih.gov/pubmed/12717015",
        "http://www.ncbi.nlm.nih.gov/pubmed/30409119"
      ]
    },
    {
      "id": "63f03c47f36125a42600001e",
      "type": "factoid",
      "body": "ZF2001 is used for which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35034583",
          "text": "e (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibod",
          "offsetInBeginSection": 670,
          "offsetInEndSection": 820,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
          "text": "To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 259,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
          "text": " CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V",
          "offsetInBeginSection": 292,
          "offsetInEndSection": 442,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
          "text": "iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
          "text": "es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ",
          "offsetInBeginSection": 598,
          "offsetInEndSection": 748,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
          "text": "Background\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 216,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
          "text": "eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased",
          "offsetInBeginSection": 2528,
          "offsetInEndSection": 2678,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
          "text": "or the three groups (P=0.0005, P<0.0001, and P<0.0001).\n\n\nConclusion\nHeterologous boosting with ZF2001 was safe and immunogenic, and prime-boost inter",
          "offsetInBeginSection": 1350,
          "offsetInEndSection": 1500,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
          "text": "Conclusion\nSARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients.",
          "offsetInBeginSection": 1440,
          "offsetInEndSection": 1543,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35634276",
        "http://www.ncbi.nlm.nih.gov/pubmed/34021265",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158819",
        "http://www.ncbi.nlm.nih.gov/pubmed/34877393",
        "http://www.ncbi.nlm.nih.gov/pubmed/35617368",
        "http://www.ncbi.nlm.nih.gov/pubmed/35596222",
        "http://www.ncbi.nlm.nih.gov/pubmed/36426361",
        "http://www.ncbi.nlm.nih.gov/pubmed/35034583"
      ]
    },
    {
      "id": "642c82c557b1c7a315000012",
      "type": "factoid",
      "body": "What mammal has the lowest known chromosome number?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
          "text": "The species have 2n=36, a number considered as a pleisomorphic feature in Arecoideae since the modern species, according to floral morphology, have the lowest chromosome number (2n=28 and 2n=30).",
          "offsetInBeginSection": 1087,
          "offsetInEndSection": 1282,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
          "text": "kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes",
          "offsetInBeginSection": 486,
          "offsetInEndSection": 636,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
          "text": "This system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\u00a0=\u00a03).",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25372387",
          "text": "ccur in nearby mountains (Hylomyscus and Beamys) were not recorded. Myosorex zinki, the only mammal endemic to Mt. Kilimanjaro, which previously was k",
          "offsetInBeginSection": 797,
          "offsetInEndSection": 947,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
          "text": "Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\u00a0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.",
          "offsetInBeginSection": 615,
          "offsetInEndSection": 848,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
          "text": " patchy distribution, poor records and low abundances. It is also the phyllotine with the lowest known diploid chromosome number (2n = 18), however it",
          "offsetInBeginSection": 74,
          "offsetInEndSection": 224,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
          "text": "The referred species presented the lowest chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region.",
          "offsetInBeginSection": 449,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/5444269",
          "text": "The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
          "text": "o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 295,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
          "text": "The chocolate gourami, Sphaerichthys osphromonoides, has the lowest chromosome number reported for fishes, with 2n = 16 and n = 8.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31879909",
        "http://www.ncbi.nlm.nih.gov/pubmed/29706521",
        "http://www.ncbi.nlm.nih.gov/pubmed/32843950",
        "http://www.ncbi.nlm.nih.gov/pubmed/22105874",
        "http://www.ncbi.nlm.nih.gov/pubmed/27186334",
        "http://www.ncbi.nlm.nih.gov/pubmed/4841572",
        "http://www.ncbi.nlm.nih.gov/pubmed/25379715",
        "http://www.ncbi.nlm.nih.gov/pubmed/25372387",
        "http://www.ncbi.nlm.nih.gov/pubmed/24500949",
        "http://www.ncbi.nlm.nih.gov/pubmed/5444269"
      ]
    },
    {
      "id": "6429b41757b1c7a315000004",
      "type": "list",
      "body": "When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30582583",
          "text": "Chromatin is subject to an array of diverse posttranslational modifications (PTMs) that mostly occur in the amino termini of histone proteins (i.e., histone tail) and regulate the accessibility and functional state of the underlying DNA.",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
          "text": "n structure and function by modifying the biochemical properties of key amino acids. Histone methylation events, especially on arginine- and lysine-re",
          "offsetInBeginSection": 329,
          "offsetInEndSection": 479,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10825229",
          "text": "The most well studied posttranslational modification of histones is the acetylation of epsilon-amino groups on conserved lysine residues in the histones' amino-terminal tail domains.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 396,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27423860",
          "text": "Overall histone acetylation states are assessed from complete protease digestion to single amino acids, which is followed by MS analysis.",
          "offsetInBeginSection": 607,
          "offsetInEndSection": 744,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16987819",
          "text": "Biochemical assays on histone peptides show that essentially all epigenetic modifications on the 21 N-terminal amino acids of histone H3 cause a significant reduction in enzymatic activity.",
          "offsetInBeginSection": 294,
          "offsetInEndSection": 483,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11395403",
          "text": "Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22122749",
        "http://www.ncbi.nlm.nih.gov/pubmed/30582583",
        "http://www.ncbi.nlm.nih.gov/pubmed/10825229",
        "http://www.ncbi.nlm.nih.gov/pubmed/16987819",
        "http://www.ncbi.nlm.nih.gov/pubmed/11395403",
        "http://www.ncbi.nlm.nih.gov/pubmed/27423860"
      ]
    },
    {
      "id": "643305b257b1c7a315000025",
      "type": "factoid",
      "body": "Which company produces Ruconest?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31592791",
          "text": "Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).",
          "offsetInBeginSection": 383,
          "offsetInEndSection": 619,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
          "text": "This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(\u00ae) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.",
          "offsetInBeginSection": 821,
          "offsetInEndSection": 1043,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
          "text": "Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
          "text": "At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.",
          "offsetInBeginSection": 651,
          "offsetInEndSection": 875,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278067",
          "text": "as follows: EUR 15,226 per QALY (Ruconest(\u00ae)) and EUR 27,786 per QALY (Berinert(\u00ae) P). The probability of cost-utility (ICUR < EUR 24,279 per QALY) as",
          "offsetInBeginSection": 1167,
          "offsetInEndSection": 1317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34832963",
          "text": "a-derived Berinert\u00ae) or immune reaction (human recombinant C1INH from rabbit milk, Ruconest\u00ae). This study describes the physicochemical and biological",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24278067",
        "http://www.ncbi.nlm.nih.gov/pubmed/25673959",
        "http://www.ncbi.nlm.nih.gov/pubmed/26106828",
        "http://www.ncbi.nlm.nih.gov/pubmed/34832963",
        "http://www.ncbi.nlm.nih.gov/pubmed/26250409",
        "http://www.ncbi.nlm.nih.gov/pubmed/31592791"
      ]
    },
    {
      "id": "641635fa690f196b5100001c",
      "type": "factoid",
      "body": "What is usually the age of diagnosis in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
          "text": "Duchenne Muscular Dystrophy (DMD) is the most frequent muscular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16638505",
          "text": "ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ",
          "offsetInBeginSection": 237,
          "offsetInEndSection": 387,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
          "text": "The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.",
          "offsetInBeginSection": 137,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
          "text": " walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su",
          "offsetInBeginSection": 178,
          "offsetInEndSection": 328,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "RESULTS\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "METHODS\nOnline surveys were sent to three groups: (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (\u226514 years), (b) parents and guardians and (c) neuromuscular clinicians in the UK NorthStar Clinical Network.",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 645,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24814059",
          "text": "METHODS\nWe performed a cross-sectional analysis of electrical impedance myography and quantitative ultrasound in 24 healthy boys and 24 with Duchenne muscular dystrophy, aged 2 to 14 years with trained research assistants performing all measurements.",
          "offsetInBeginSection": 391,
          "offsetInEndSection": 641,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
          "text": "A well examined muscular biopsy is usually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate.",
          "offsetInBeginSection": 609,
          "offsetInEndSection": 790,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
        "http://www.ncbi.nlm.nih.gov/pubmed/7334343",
        "http://www.ncbi.nlm.nih.gov/pubmed/24814059",
        "http://www.ncbi.nlm.nih.gov/pubmed/26022172",
        "http://www.ncbi.nlm.nih.gov/pubmed/11929208",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/16638505"
      ]
    },
    {
      "id": "6402c868201352f04a00000b",
      "type": "yesno",
      "body": "Was erythropoietin effective for optic neuritis in the TONE trial?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "INTERPRETATION\nThese results give the first indications that erythropoietin might be neuroprotective in optic neuritis.",
          "offsetInBeginSection": 1767,
          "offsetInEndSection": 1886,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9103884",
          "text": "ned pathology, therapy of this disease, and summarized our previous cases. Intravenous methylpredonisolone treatment is effective from our experience.",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
          "text": "icosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30151023",
          "text": "ears and provided valuable data about clinical course, efficacy of steroid treatment, and risk of conversion to MS. Compared to the many studies in We",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 480,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
          "text": "ys or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started ",
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1697,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
          "text": "oup than in the control (P<.05).\n\n\nCONCLUSIONS\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in ",
          "offsetInBeginSection": 1064,
          "offsetInEndSection": 1214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
          "text": "OBJECTIVE\nTo investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
          "text": "OBJECTIVE\nBased on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22926853",
        "http://www.ncbi.nlm.nih.gov/pubmed/35501141",
        "http://www.ncbi.nlm.nih.gov/pubmed/26932144",
        "http://www.ncbi.nlm.nih.gov/pubmed/10340796",
        "http://www.ncbi.nlm.nih.gov/pubmed/22465890",
        "http://www.ncbi.nlm.nih.gov/pubmed/9103884",
        "http://www.ncbi.nlm.nih.gov/pubmed/30151023"
      ]
    },
    {
      "id": "6424154d690f196b5100004a",
      "type": "summary",
      "body": "What is the R value with respect to hepatoxicity",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33620007",
          "text": "Overall, 79 cases (76%) had no acute liver injury or hepatotoxicity, and 25 (24%) developed hepatoxicity.",
          "offsetInBeginSection": 1007,
          "offsetInEndSection": 1112,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33620007"
      ]
    },
    {
      "id": "64299b6a57b1c7a315000001",
      "type": "yesno",
      "body": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36367927",
          "text": " caused by the Omicron variant in renal transplant recipients (RTRs) is unknown.\n\n\nMETHODS\nInterviews were conducted with 447 RTRs regarding the statu",
          "offsetInBeginSection": 136,
          "offsetInEndSection": 286,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36238984",
          "text": "ronavirus Disease 2019 (COVID-19)\u00a0pandemic in Shanghai, but over 90% of patients were mild. This study included 1139 COVID-19 patients mildly infected",
          "offsetInBeginSection": 119,
          "offsetInEndSection": 269,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
          "text": "BACKGROUND\nIn the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36072085",
          "text": "Unlike the previous two waves, COVID-19 due to the Omicron variant\u00a0was less severe with only 5% of hemodialysis patients\u00a0requiring admission to the intensive care unit compared to 25% during the previous waves.",
          "offsetInBeginSection": 792,
          "offsetInEndSection": 1002,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
          "text": "Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2.",
          "offsetInBeginSection": 1292,
          "offsetInEndSection": 1477,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "ly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiven",
          "offsetInBeginSection": 1314,
          "offsetInEndSection": 1464,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
          "text": "ively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization co",
          "offsetInBeginSection": 1963,
          "offsetInEndSection": 2113,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
          "text": "Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.",
          "offsetInBeginSection": 372,
          "offsetInEndSection": 591,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
          "text": "However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.",
          "offsetInBeginSection": 772,
          "offsetInEndSection": 903,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36090988",
        "http://www.ncbi.nlm.nih.gov/pubmed/36238984",
        "http://www.ncbi.nlm.nih.gov/pubmed/35869843",
        "http://www.ncbi.nlm.nih.gov/pubmed/36466505",
        "http://www.ncbi.nlm.nih.gov/pubmed/35583528",
        "http://www.ncbi.nlm.nih.gov/pubmed/36285226",
        "http://www.ncbi.nlm.nih.gov/pubmed/36367927",
        "http://www.ncbi.nlm.nih.gov/pubmed/36072085"
      ]
    },
    {
      "id": "6432ffdf57b1c7a315000021",
      "type": "summary",
      "body": "What is hereditary angioedema?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3397981",
          "text": "t with hereditary angioedema. Hereditary angioedema, one of the inherited complement deficiencies, has been reported in association with a number of a",
          "offsetInBeginSection": 75,
          "offsetInEndSection": 225,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
          "text": "In addition to edema of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 718,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
          "text": "The disease can either present with hypocomplementemia owing to the presence of pathogenic variants in the gene encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevated estrogen levels owing to gain-of-function variants in the genes encoding coagulation proteins involved in the kallikrein-kinin system (namely, coagulation FXII [FXII-associated hereditary angioedema], plasminogen [PLG-associated hereditary angioedema], and high-molecular-weight kininogen [KNG1-associated hereditary angioedema]).",
          "offsetInBeginSection": 603,
          "offsetInEndSection": 1195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
          "text": "Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
          "text": "Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1-esterase inhibitor of the classic complement pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22073494",
          "text": "Hereditary angioedema is a rare form of angioedema that can be diagnosed by screening with a C4 level.",
          "offsetInBeginSection": 322,
          "offsetInEndSection": 424,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31283393",
          "text": "Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34904566",
          "text": "INTRODUCTION\nHereditary angioedema is an infrequent genetic disorder; which mainly manifests with cutaneous and mucosal swelling.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
          "text": "Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
          "text": "Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34904566",
        "http://www.ncbi.nlm.nih.gov/pubmed/33233873",
        "http://www.ncbi.nlm.nih.gov/pubmed/22179171",
        "http://www.ncbi.nlm.nih.gov/pubmed/19849675",
        "http://www.ncbi.nlm.nih.gov/pubmed/22195758",
        "http://www.ncbi.nlm.nih.gov/pubmed/32178893",
        "http://www.ncbi.nlm.nih.gov/pubmed/22073494",
        "http://www.ncbi.nlm.nih.gov/pubmed/31283393",
        "http://www.ncbi.nlm.nih.gov/pubmed/22227095",
        "http://www.ncbi.nlm.nih.gov/pubmed/3397981"
      ]
    },
    {
      "id": "64178ec2690f196b51000024",
      "type": "summary",
      "body": "What is viltolarsen's mechanism of action?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.",
          "offsetInBeginSection": 201,
          "offsetInEndSection": 381,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
          "text": "In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 278,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
          "text": "However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 319,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
          "text": "ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 305,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089283",
          "text": "The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
          "text": "mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N",
          "offsetInBeginSection": 227,
          "offsetInEndSection": 377,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
          "text": "nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ",
          "offsetInBeginSection": 1422,
          "offsetInEndSection": 1572,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
          "text": "These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.",
          "offsetInBeginSection": 1011,
          "offsetInEndSection": 1205,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
          "text": "ialdehyde antimicrobial agent, the mechanism of action of which has been little studied. The aims of this paper are to examine what is currently known",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6572387",
          "text": "enylate cyclase activities that are stimulated by human chorionic gonadotropin (hCG) and thyrotropin, respectively. Both cell types also respond to ch",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20735416",
        "http://www.ncbi.nlm.nih.gov/pubmed/25544661",
        "http://www.ncbi.nlm.nih.gov/pubmed/29178131",
        "http://www.ncbi.nlm.nih.gov/pubmed/6572387",
        "http://www.ncbi.nlm.nih.gov/pubmed/10029375",
        "http://www.ncbi.nlm.nih.gov/pubmed/34826604",
        "http://www.ncbi.nlm.nih.gov/pubmed/11068911",
        "http://www.ncbi.nlm.nih.gov/pubmed/27324312",
        "http://www.ncbi.nlm.nih.gov/pubmed/23089283"
      ]
    },
    {
      "id": "64040bd8201352f04a00000e",
      "type": "yesno",
      "body": "Should be used bexarotene for relapsing-remitting multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19242067",
          "text": "ified as having Relapsing-Remitting Multiple Sclerosis accordingly with Lublin were collected for oxidative stress markers quantification.\n\n\nRESULTS\nN",
          "offsetInBeginSection": 341,
          "offsetInEndSection": 491,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26701666",
          "text": "We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 675,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21975773",
          "text": "y profile of NTZ is warranted. NTZ should be used only by skilled neurologists in MS centres under surveillance programs.All the data in this review c",
          "offsetInBeginSection": 4062,
          "offsetInEndSection": 4212,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23994714",
          "text": "remitting multiple sclerosis was treated with immunomodulatory agents, interferon \u03b2 or glatiramer acetate. The secondary progressive multiple sclerosi",
          "offsetInBeginSection": 703,
          "offsetInEndSection": 853,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14978418",
          "text": "It can also be used in secondary progressive and progressive relapsing remitting multiple sclerosis.",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 210,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28639482",
          "text": "Additionally, a match between being adequately challenged by work, while still having the capacity to meet those work demands, is needed, as is long-term financial stability.",
          "offsetInBeginSection": 1243,
          "offsetInEndSection": 1417,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099778",
          "text": "The data presented in the current work may be used for the construction of a biomarker panel, to differentiate primary progressive and relapsing-remitting courses of multiple sclerosis on the initial stages of the disease.",
          "offsetInBeginSection": 1032,
          "offsetInEndSection": 1254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35652121",
          "text": "Myelin-sensitive MRI such as magnetization transfer imaging has been widely used in multiple sclerosis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30042638",
          "text": "Thus, it is consequential to emphasize the value of tailored intervention for attending to these factors in the treatment and rehabilitation agendas for improvement of health-related quality of life in relapsing-remitting multiple sclerosis.",
          "offsetInBeginSection": 1809,
          "offsetInEndSection": 2050,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31099778",
        "http://www.ncbi.nlm.nih.gov/pubmed/30042638",
        "http://www.ncbi.nlm.nih.gov/pubmed/21975773",
        "http://www.ncbi.nlm.nih.gov/pubmed/23994714",
        "http://www.ncbi.nlm.nih.gov/pubmed/19242067",
        "http://www.ncbi.nlm.nih.gov/pubmed/26701666",
        "http://www.ncbi.nlm.nih.gov/pubmed/28639482",
        "http://www.ncbi.nlm.nih.gov/pubmed/14978418",
        "http://www.ncbi.nlm.nih.gov/pubmed/35652121"
      ]
    },
    {
      "id": "6422e7f0690f196b51000045",
      "type": "list",
      "body": "Hepcidin is a key regulator of what processes?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531037",
          "text": "BACKGROUND\nHepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may con",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23807042",
          "text": "BACKGROUND\nHepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable ",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
          "text": "Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
          "text": "Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19249912",
          "text": "Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293278",
          "text": "Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15886319",
          "text": "Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25782630",
          "text": "Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16198622",
          "text": "Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.",
          "offsetInBeginSection": 126,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
          "text": "Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23807042",
        "http://www.ncbi.nlm.nih.gov/pubmed/24293278",
        "http://www.ncbi.nlm.nih.gov/pubmed/16497104",
        "http://www.ncbi.nlm.nih.gov/pubmed/19681654",
        "http://www.ncbi.nlm.nih.gov/pubmed/16198622",
        "http://www.ncbi.nlm.nih.gov/pubmed/21136948",
        "http://www.ncbi.nlm.nih.gov/pubmed/15886319",
        "http://www.ncbi.nlm.nih.gov/pubmed/25782630",
        "http://www.ncbi.nlm.nih.gov/pubmed/23531037",
        "http://www.ncbi.nlm.nih.gov/pubmed/19249912"
      ]
    },
    {
      "id": "6429ee7457b1c7a31500000b",
      "type": "yesno",
      "body": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
          "text": "The COVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such occurrences.",
          "offsetInBeginSection": 144,
          "offsetInEndSection": 311,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36276167",
          "text": "when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals an",
          "offsetInBeginSection": 1264,
          "offsetInEndSection": 1414,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
          "text": "tients with BECTS reported having side effects; all effects were mild that could be relieved themselves. For Sinopharm (Beijing): BBIBP-CorV (Vero cel",
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1010,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
          "text": "The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%).",
          "offsetInBeginSection": 1062,
          "offsetInEndSection": 1182,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
          "text": "etween 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.\n\n\nConclusions\nAccording t",
          "offsetInBeginSection": 1514,
          "offsetInEndSection": 1664,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
          "text": "cination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater",
          "offsetInBeginSection": 2211,
          "offsetInEndSection": 2361,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
          "text": "The common side effects reported following Covid-19 vaccination were mostly self-restricted local reactions that resolved quickly.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 391,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767100",
          "text": "The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX).",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 921,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
          "text": "d individuals with DS (median age = 19.5\u00a0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v",
          "offsetInBeginSection": 943,
          "offsetInEndSection": 1093,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
          "text": "period of 3-13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent d",
          "offsetInBeginSection": 709,
          "offsetInEndSection": 859,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35334998",
        "http://www.ncbi.nlm.nih.gov/pubmed/34940894",
        "http://www.ncbi.nlm.nih.gov/pubmed/35738594",
        "http://www.ncbi.nlm.nih.gov/pubmed/35383912",
        "http://www.ncbi.nlm.nih.gov/pubmed/35775049",
        "http://www.ncbi.nlm.nih.gov/pubmed/36276167",
        "http://www.ncbi.nlm.nih.gov/pubmed/35952506",
        "http://www.ncbi.nlm.nih.gov/pubmed/34197678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35244157",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767100"
      ]
    },
    {
      "id": "6433050157b1c7a315000024",
      "type": "factoid",
      "body": "Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
          "text": "BACKGROUND\nConestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
          "text": "BACKGROUND\nRecombinant human C1-inhibitor (rhC1INH; Ruconest\u00ae) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021471",
          "text": " an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg",
          "offsetInBeginSection": 219,
          "offsetInEndSection": 369,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30280305",
          "text": "Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH).",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 941,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32923264",
          "text": "The targeted therapy for HAE consists of plasma-derived or recombinant C1-INH, ecallantide, and icatibant or bradykinin receptor antagonist.",
          "offsetInBeginSection": 577,
          "offsetInEndSection": 717,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21753889",
          "text": "n findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement product",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 358,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
          "text": "tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze\u00ae is a nanofiltered C1-INH, approved in Europe for the acute treatment, ",
          "offsetInBeginSection": 388,
          "offsetInEndSection": 538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
          "text": " likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is",
          "offsetInBeginSection": 396,
          "offsetInEndSection": 546,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21753889",
        "http://www.ncbi.nlm.nih.gov/pubmed/30280305",
        "http://www.ncbi.nlm.nih.gov/pubmed/22171564",
        "http://www.ncbi.nlm.nih.gov/pubmed/24556385",
        "http://www.ncbi.nlm.nih.gov/pubmed/17559913",
        "http://www.ncbi.nlm.nih.gov/pubmed/29569504",
        "http://www.ncbi.nlm.nih.gov/pubmed/32923264",
        "http://www.ncbi.nlm.nih.gov/pubmed/30021471"
      ]
    },
    {
      "id": "6417900b690f196b5100002a",
      "type": "factoid",
      "body": "What type of DMD can viltolarsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
          "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 305,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
          "text": "nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p",
          "offsetInBeginSection": 167,
          "offsetInEndSection": 317,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
          "text": "n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
          "text": "disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta",
          "offsetInBeginSection": 420,
          "offsetInEndSection": 570,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
          "text": "Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.",
          "offsetInBeginSection": 483,
          "offsetInEndSection": 569,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
        "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
        "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
        "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
        "http://www.ncbi.nlm.nih.gov/pubmed/29579701"
      ]
    },
    {
      "id": "63f57ea133942b094c000005",
      "type": "list",
      "body": "What is the triad of the Cat eye syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
          "text": "The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
          "text": "osome 22q11. The patients demonstrate specific abnormalities of heart, kidney, and eye. Here we attempted to produce a model for this defect by expres",
          "offsetInBeginSection": 84,
          "offsetInEndSection": 234,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
          "text": "The cat eye syndrome, blepharophimosis or Kohn-Romano syndrome, Rieger syndrome, and other disorders are discussed in relationship to this entity.",
          "offsetInBeginSection": 236,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
          "text": "riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise",
          "offsetInBeginSection": 46,
          "offsetInEndSection": 196,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/410302",
          "text": "hniques, we studied a child with typical cat-eye syndrome and ocular retraction syndrome. Although the mother was was chromosomally normal, other mate",
          "offsetInBeginSection": 38,
          "offsetInEndSection": 188,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35911297",
          "text": "The classic clinical triad includes coloboma of the iris, ears, and anal malformations.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 188,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
          "text": "In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosome.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
          "text": "e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p",
          "offsetInBeginSection": 129,
          "offsetInEndSection": 279,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31034246",
          "text": "Most of the sample was assigned moderate or high risk for Triad CRA and RED-S CAT (Triad: 54.7% moderate and 7.9% high; RED-S: 63.2% moderate and 33.0% high).",
          "offsetInBeginSection": 964,
          "offsetInEndSection": 1122,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648072",
          "text": "Individuals with cat-eye syndrome are characterized by the presence of preauricular pits and/or tags, anal atresia, and iris coloboma.",
          "offsetInBeginSection": 67,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23928108",
        "http://www.ncbi.nlm.nih.gov/pubmed/25648072",
        "http://www.ncbi.nlm.nih.gov/pubmed/2072964",
        "http://www.ncbi.nlm.nih.gov/pubmed/410302",
        "http://www.ncbi.nlm.nih.gov/pubmed/11332976",
        "http://www.ncbi.nlm.nih.gov/pubmed/31034246",
        "http://www.ncbi.nlm.nih.gov/pubmed/33465332",
        "http://www.ncbi.nlm.nih.gov/pubmed/3109242",
        "http://www.ncbi.nlm.nih.gov/pubmed/16145841",
        "http://www.ncbi.nlm.nih.gov/pubmed/35911297"
      ]
    },
    {
      "id": "64281a47690f196b5100004f",
      "type": "yesno",
      "body": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34258537",
          "text": "INTRODUCTION\nThe therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
          "text": "combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in pa",
          "offsetInBeginSection": 268,
          "offsetInEndSection": 418,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1",
          "offsetInBeginSection": 69,
          "offsetInEndSection": 219,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
          "text": "1), with doses and intervals according to body weight. Little is known as to its use in infants; the aim of this study was to describe treatment outco",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 277,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
          "text": "Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production.",
          "offsetInBeginSection": 194,
          "offsetInEndSection": 304,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22215125",
          "text": "The primary disease is treated by combined liver-kidney transplantation, although pathological fracturing also occurs in the posttransplant period.",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 510,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830800",
          "text": "Aside from combined liver/kidney transplantation, no curative treatment exists.",
          "offsetInBeginSection": 300,
          "offsetInEndSection": 379,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
          "text": "Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients.",
          "offsetInBeginSection": 1561,
          "offsetInEndSection": 1673,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35071135",
          "text": "ney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxalate prod",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
          "text": "NA interference medication is now available. Lumasiran\u00ae is already available on prescription and targets the messenger RNA of glycolate oxidase, thus ",
          "offsetInBeginSection": 781,
          "offsetInEndSection": 931,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22215125",
        "http://www.ncbi.nlm.nih.gov/pubmed/35779234",
        "http://www.ncbi.nlm.nih.gov/pubmed/31580236",
        "http://www.ncbi.nlm.nih.gov/pubmed/35015123",
        "http://www.ncbi.nlm.nih.gov/pubmed/33985991",
        "http://www.ncbi.nlm.nih.gov/pubmed/34258537",
        "http://www.ncbi.nlm.nih.gov/pubmed/32165440",
        "http://www.ncbi.nlm.nih.gov/pubmed/23830800",
        "http://www.ncbi.nlm.nih.gov/pubmed/35071135"
      ]
    },
    {
      "id": "6429cfb557b1c7a315000005",
      "type": "yesno",
      "body": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
          "text": "ated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate th",
          "offsetInBeginSection": 1675,
          "offsetInEndSection": 1825,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
          "text": "ociated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate",
          "offsetInBeginSection": 1672,
          "offsetInEndSection": 1822,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
          "text": "Asthma should be managed as outlined in local and international guidelines.Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 603,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12877818",
          "text": "Although inhaled glucocorticoids are highly effective in controlling airway inflammation in asthma, they are ineffective in the small group of patients with glucocorticoid-dependent and -resistant asthma.",
          "offsetInBeginSection": 127,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35747745",
          "text": "ions such as inhaled corticosteroids (ICS) and biologics on COVID-19 is unclear. This systematic literature review analyzed the published evidence on ",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33248363",
          "text": "Considering what is available in literature, there are no known infection-related hazards to an uninfected patient and also a patient with COVID-19 that preclude the use of a nebulizer at home, but it fundamental that all patients, regardless of whether or not suffering from COVID-19, always follow some practical advices.",
          "offsetInBeginSection": 1066,
          "offsetInEndSection": 1389,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34568369",
          "text": ". 007 \u00b1 0.38; P < 0.05) during the COVID-19 pandemic. In contrast, among COPD patients, there were no significant differences in AE frequency, clinic ",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750734",
          "text": " also enhance the efficacy of inhaled glucocorticoids in chronic obstructive pulmonary disease (COPD). In both conditions, these drugs are believed to",
          "offsetInBeginSection": 846,
          "offsetInEndSection": 996,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35887681",
          "text": "In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities.",
          "offsetInBeginSection": 1791,
          "offsetInEndSection": 1935,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
          "text": "CONCLUSIONS\nOur study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.",
          "offsetInBeginSection": 1477,
          "offsetInEndSection": 1726,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34476396",
        "http://www.ncbi.nlm.nih.gov/pubmed/33248363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35887681",
        "http://www.ncbi.nlm.nih.gov/pubmed/25750734",
        "http://www.ncbi.nlm.nih.gov/pubmed/34222281",
        "http://www.ncbi.nlm.nih.gov/pubmed/33276252",
        "http://www.ncbi.nlm.nih.gov/pubmed/34568369",
        "http://www.ncbi.nlm.nih.gov/pubmed/35747745",
        "http://www.ncbi.nlm.nih.gov/pubmed/12877818"
      ]
    },
    {
      "id": "6432f75757b1c7a31500001d",
      "type": "yesno",
      "body": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34276674",
          "text": "At present, three different covalent BTKis, ibrutinib, acalabrutinib and zanubrutinib, are FDA-approved and many new inhibitors are under development.",
          "offsetInBeginSection": 406,
          "offsetInEndSection": 556,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved potential for combination with other targeted therapies.",
          "offsetInBeginSection": 798,
          "offsetInEndSection": 995,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
          "text": "TKi-related adverse events, but major rates of neutropenia, and its approval is awaited. With the aim of overcoming drug resistance, noncovalent BTKi ",
          "offsetInBeginSection": 676,
          "offsetInEndSection": 826,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
          "text": "Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32731259",
          "text": ", a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease w",
          "offsetInBeginSection": 198,
          "offsetInEndSection": 348,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have",
          "offsetInBeginSection": 3152,
          "offsetInEndSection": 3302,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "ater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle",
          "offsetInBeginSection": 511,
          "offsetInEndSection": 661,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35507054",
          "text": "labrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our",
          "offsetInBeginSection": 165,
          "offsetInEndSection": 315,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
          "text": "Whether zanubrutinib, a second-generation selective BTK inhibitor, has similar effects as ibrutinib remains to be determined.",
          "offsetInBeginSection": 203,
          "offsetInEndSection": 328,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35507054",
        "http://www.ncbi.nlm.nih.gov/pubmed/31420873",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/34276674",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484067",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/35993294",
        "http://www.ncbi.nlm.nih.gov/pubmed/32731259"
      ]
    },
    {
      "id": "64178fea690f196b51000028",
      "type": "factoid",
      "body": "What types of DMD can eteplirsen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
          "text": "OBJECTIVE\nIn prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
          "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
          "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
          "text": "BACKGROUND\nExon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909",
          "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production.ObjectiveTo report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficacy and safety of eteplirsen in a larger cohort.MethodsAmbulatory patients aged 7-16 years, with confirmed mutations amenable to exon 51 skipping, received eteplirsen 30\u200amg/kg/week intravenously for 96 weeks.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 501,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31261494",
          "text": "This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
          "text": "Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.",
          "offsetInBeginSection": 135,
          "offsetInEndSection": 346,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
          "text": "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 544,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29752304",
          "text": "OBJECTIVE\nTo describe the quantification of novel dystrophin production in patients with Duchenne muscular dystrophy (DMD) after long-term treatment with eteplirsen.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
        "http://www.ncbi.nlm.nih.gov/pubmed/34120909",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/29907124",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526286",
        "http://www.ncbi.nlm.nih.gov/pubmed/23907995",
        "http://www.ncbi.nlm.nih.gov/pubmed/29752304",
        "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
        "http://www.ncbi.nlm.nih.gov/pubmed/31261494"
      ]
    },
    {
      "id": "63eef94ff36125a426000010",
      "type": "yesno",
      "body": "Is Cinpanemab effective for Parkinson\u2019s Disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "The trial was stopped after the week 72 interim analysis owing to lack of efficacy.",
          "offsetInBeginSection": 1215,
          "offsetInEndSection": 1298,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
          "text": "Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID).",
          "offsetInBeginSection": 105,
          "offsetInEndSection": 323,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
          "text": "Cinpanemab, a human-derived monoclonal antibody that binds to \u03b1-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
          "text": "in patients with Parkinson\u2019s disease (PD). However, its therapeutic mechanism of action is unknown. The healthy striatum exhibits rich dynamics result",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 267,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
          "text": "The present therapeutic drugs for PD can only alleviate the patients\u2019 symptoms, but cannot prevent or delay progression of the disease.",
          "offsetInBeginSection": 114,
          "offsetInEndSection": 249,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
          "text": "Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect.",
          "offsetInBeginSection": 308,
          "offsetInEndSection": 416,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
          "text": "Conclusion\nAs detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.",
          "offsetInBeginSection": 1067,
          "offsetInEndSection": 1241,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
          "text": " associated with neurodegeneration  but  have  failed  to  identify  preventive  or  curative  therapies.  This  failure  mainly  originates  from  th",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 383,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
          "text": "The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection.",
          "offsetInBeginSection": 147,
          "offsetInEndSection": 330,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29714967",
          "text": "Parkinson\u2019s disease(PD)diagnosis based on speech data has been proved to be an effective way in recent years.There are still some problems on preprocessing samples,ensemble learning,and so on.The problems can further cause misleading of classifiers,unsatisfactory classification accuracy and stability.This paper proposed a new diagnosis algorithm of PD by combining multi-edit sample selection method and random forest.At the end of it,this paper presents a group of experiments carried out with the newest public datasets.Experimental results showed that this proposed algorithm realized the classification of the samples and the subjects of PD.Furthermore,it achieved average classification accuracy of 100% and obtained improvement of up to 29.44% compared to those provided by the subjects.This paper proposes a new speech diagnosis algorithm for PD based on instance selection;and the method algorithm has a higher and more stable classification accuracy,compared with the other algorithms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 996,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26236796",
        "http://www.ncbi.nlm.nih.gov/pubmed/29874003",
        "http://www.ncbi.nlm.nih.gov/pubmed/23223310",
        "http://www.ncbi.nlm.nih.gov/pubmed/35921450",
        "http://www.ncbi.nlm.nih.gov/pubmed/35404466",
        "http://www.ncbi.nlm.nih.gov/pubmed/35500112",
        "http://www.ncbi.nlm.nih.gov/pubmed/31731332",
        "http://www.ncbi.nlm.nih.gov/pubmed/26464310",
        "http://www.ncbi.nlm.nih.gov/pubmed/29714967"
      ]
    },
    {
      "id": "6426d131690f196b5100004e",
      "type": "factoid",
      "body": "In what organ would you find the Ashwell receptor?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
          "text": "The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27207430",
          "text": "This review will focus on the mechanisms of platelet senescence with specific emphasis on the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
          "text": "Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.",
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1088,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18488037",
        "http://www.ncbi.nlm.nih.gov/pubmed/20816169",
        "http://www.ncbi.nlm.nih.gov/pubmed/27207430"
      ]
    },
    {
      "id": "6429e17657b1c7a315000007",
      "type": "list",
      "body": "What histone marks are indicative of enhancers in the chromatin landscape of a given cell?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649883",
          "text": "or instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac. The traditional bottom-up MS strategy identifies and quantifies",
          "offsetInBeginSection": 417,
          "offsetInEndSection": 567,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
          "text": "In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 939,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
          "text": "The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.",
          "offsetInBeginSection": 996,
          "offsetInEndSection": 1339,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957309",
          "text": "We tested 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of active enhancers.",
          "offsetInBeginSection": 347,
          "offsetInEndSection": 523,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
          "text": "In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.",
          "offsetInBeginSection": 725,
          "offsetInEndSection": 939,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
          "text": "These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 450,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32286315",
          "text": "Here, we present chromatin immunoprecipitation sequencing (ChIP-Seq) data for the oncogenic transcription factors, MYCN and MYC, as well as regulatory histone marks H3K4me1, H3K4me3, H3K27Ac, and H3K27me3 in ten commonly used human neuroblastoma-derived cell line models.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 479,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
          "text": "stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements ",
          "offsetInBeginSection": 667,
          "offsetInEndSection": 817,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955985",
          "text": "all types of chromatin marks examined, including promoter, enhancer, elongation, and repressive marks. The fine-resolution signal shapes discovered by",
          "offsetInBeginSection": 1403,
          "offsetInEndSection": 1553,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22955985",
          "text": "digestion and high-depth sequencing. Here we relate 14 chromatin signals (12 histone marks, DNase, and nucleosome positioning) to the binding sites of",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 603,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28981749",
        "http://www.ncbi.nlm.nih.gov/pubmed/32058623",
        "http://www.ncbi.nlm.nih.gov/pubmed/21106759",
        "http://www.ncbi.nlm.nih.gov/pubmed/28649883",
        "http://www.ncbi.nlm.nih.gov/pubmed/32286315",
        "http://www.ncbi.nlm.nih.gov/pubmed/26957309",
        "http://www.ncbi.nlm.nih.gov/pubmed/29089515",
        "http://www.ncbi.nlm.nih.gov/pubmed/22955985"
      ]
    },
    {
      "id": "643306cc57b1c7a315000027",
      "type": "yesno",
      "body": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35719360",
          "text": "0 min), and CRISPR/Cas12a-mediated detection (37\u00b0C, 8 min), can be completed within 70 min. A fluorescence reader (for fluorescence CRISPR-CLA) or a l",
          "offsetInBeginSection": 1652,
          "offsetInEndSection": 1802,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
          "text": "These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to detect all types of pathogens.",
          "offsetInBeginSection": 1008,
          "offsetInEndSection": 1165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33159392",
          "text": "However, whether single-stranded DNA in CRISPR system can cause false positives remains undetermined.",
          "offsetInBeginSection": 202,
          "offsetInEndSection": 303,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
          "text": "h attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules. Bacterial allosteric transcription factors (",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
          "text": "This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.",
          "offsetInBeginSection": 1361,
          "offsetInEndSection": 1562,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33329659",
          "text": "By using this simple and high-efficiency CRISPR/Cas12a system, multiple targets can be modified to obtain multigene simultaneous knockout mutants in tree species, which will provide powerful tools with which to facilitate genetic studies of forest trees.",
          "offsetInBeginSection": 1212,
          "offsetInEndSection": 1466,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
          "text": "ns-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection. Herein, we introduce a new type of Cas12a reporter, G-triplex ",
          "offsetInBeginSection": 24,
          "offsetInEndSection": 174,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34794559",
          "text": "By means of the unique combination of Cas12a with ECL technique based on BPE, it can convert the recognition of target ATP into a detectable ECL signal.",
          "offsetInBeginSection": 720,
          "offsetInEndSection": 872,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36214815",
          "text": "e degraded, leaving the single-stranded DNA (ssDNA). The CRISPR/Cas12a can accurately locate ssDNA without PAM, then initiating its trans-cleavage act",
          "offsetInBeginSection": 868,
          "offsetInEndSection": 1018,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34653714",
          "text": "Although CRISPR-Cas12a and CRISPR-Cas13a systems work individually effective on gene detection, their multiplex detection capability is limited due to the lack of specific probe cleavage mechanism.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36214815",
        "http://www.ncbi.nlm.nih.gov/pubmed/34794559",
        "http://www.ncbi.nlm.nih.gov/pubmed/32093010",
        "http://www.ncbi.nlm.nih.gov/pubmed/35719360",
        "http://www.ncbi.nlm.nih.gov/pubmed/32486913",
        "http://www.ncbi.nlm.nih.gov/pubmed/31413315",
        "http://www.ncbi.nlm.nih.gov/pubmed/33991961",
        "http://www.ncbi.nlm.nih.gov/pubmed/33329659",
        "http://www.ncbi.nlm.nih.gov/pubmed/33159392",
        "http://www.ncbi.nlm.nih.gov/pubmed/34653714"
      ]
    },
    {
      "id": "64178ffb690f196b51000029",
      "type": "factoid",
      "body": "What type of DMD can casimersen be used for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
          "text": "Casimersen (Amondys 45\u2122) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\u00a045 skipping.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
          "text": "ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari",
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
          "text": "be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
          "text": "This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 172,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
          "text": "of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-",
          "offsetInBeginSection": 882,
          "offsetInEndSection": 1032,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29579701",
          "text": "BACKGROUND\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
          "text": "disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr",
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
          "text": "A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 271,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
          "text": "Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl",
          "offsetInBeginSection": 1478,
          "offsetInEndSection": 1628,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
          "text": "sed as potential treatments for inherited myopathies, such as Duchenne muscular dystrophy (DMD). The success of myoblast implantation in mouse models,",
          "offsetInBeginSection": 63,
          "offsetInEndSection": 213,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34569969",
        "http://www.ncbi.nlm.nih.gov/pubmed/26594036",
        "http://www.ncbi.nlm.nih.gov/pubmed/12692454",
        "http://www.ncbi.nlm.nih.gov/pubmed/7599358",
        "http://www.ncbi.nlm.nih.gov/pubmed/33861387",
        "http://www.ncbi.nlm.nih.gov/pubmed/34105177",
        "http://www.ncbi.nlm.nih.gov/pubmed/36449321",
        "http://www.ncbi.nlm.nih.gov/pubmed/25365558",
        "http://www.ncbi.nlm.nih.gov/pubmed/29791760",
        "http://www.ncbi.nlm.nih.gov/pubmed/29579701"
      ]
    },
    {
      "id": "63eeefc5f36125a426000009",
      "type": "factoid",
      "body": "What is targeted by CIS43LS?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
          "text": " dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have implications for the seasonal control of mala",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1250,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
          "text": "ody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. Part A of the trial assessed the safety, initial side-e",
          "offsetInBeginSection": 248,
          "offsetInEndSection": 398,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34379916",
          "text": "administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Aller",
          "offsetInBeginSection": 1993,
          "offsetInEndSection": 2143,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
          "text": "BACKGROUND\nCIS43LS is a monoclonal antibody that was shown to protect against controlled <i>Plasmodium falciparum</i> infection in a phase 1 clinical trial.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
          "text": "falciparum</i> infection over a 6-month malaria season in Mali without evident safety concerns.",
          "offsetInBeginSection": 1837,
          "offsetInEndSection": 1932,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
          "text": "CIS43 is a potent neutralizing human mAb that targets a highly conserved \"junctional\" epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33332286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34511592",
        "http://www.ncbi.nlm.nih.gov/pubmed/36317783",
        "http://www.ncbi.nlm.nih.gov/pubmed/34379916"
      ]
    },
    {
      "id": "6415b422690f196b5100000a",
      "type": "summary",
      "body": "What does Cal-light do?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
          "text": "We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 292,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
      ]
    },
    {
      "id": "64172bb2690f196b5100001e",
      "type": "factoid",
      "body": "To which region of a gene does an RNA polymerase bind to initiate transcription?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
          "text": "RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 363,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8065261",
          "text": "Furthermore, two proteins (M(r) 12,000 and 35,000) which interact with and may activate transcription from the ndh promoter under these conditions were detected by gel retardation analysis.",
          "offsetInBeginSection": 1234,
          "offsetInEndSection": 1423,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
          "text": "The RNA polymerase from bacteriophage T4-infected Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits and by binding several virus-encoded subunits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 246,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
          "text": "Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
          "text": "from a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces t",
          "offsetInBeginSection": 639,
          "offsetInEndSection": 789,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7022450",
          "text": "nscription at certain promoters recognized by unmodified enzyme. In the T4tRNA gene region, only one of the two promoters is active with the modified ",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
          "text": "A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.",
          "offsetInBeginSection": 246,
          "offsetInEndSection": 524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
          "text": "kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene.",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 213,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2648001",
          "text": " facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ",
          "offsetInBeginSection": 1617,
          "offsetInEndSection": 1767,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8496187",
          "text": "actor responsible for the assembly of a transcription complex on the 5 S RNA gene. We have analyzed the effect of deleting various regions of yeast TF",
          "offsetInBeginSection": 120,
          "offsetInEndSection": 270,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/6194892",
        "http://www.ncbi.nlm.nih.gov/pubmed/24600005",
        "http://www.ncbi.nlm.nih.gov/pubmed/6382259",
        "http://www.ncbi.nlm.nih.gov/pubmed/31863129",
        "http://www.ncbi.nlm.nih.gov/pubmed/8065261",
        "http://www.ncbi.nlm.nih.gov/pubmed/9603525",
        "http://www.ncbi.nlm.nih.gov/pubmed/8496187",
        "http://www.ncbi.nlm.nih.gov/pubmed/7022450",
        "http://www.ncbi.nlm.nih.gov/pubmed/3380786",
        "http://www.ncbi.nlm.nih.gov/pubmed/2648001"
      ]
    },
    {
      "id": "63f9ccdc33942b094c00000f",
      "type": "yesno",
      "body": "Is PRP-40 involved in microexon splicing?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "ion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dep",
          "offsetInBeginSection": 527,
          "offsetInEndSection": 677,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
          "text": "f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen",
          "offsetInBeginSection": 532,
          "offsetInEndSection": 682,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7935475",
          "text": "However, any such splicing factor containing the helicase motifs in vertebrates has not been identified.",
          "offsetInBeginSection": 286,
          "offsetInEndSection": 390,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
          "text": "ated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reaction",
          "offsetInBeginSection": 1307,
          "offsetInEndSection": 1457,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18945809",
          "text": "Our findings suggest that in addition to its important regulatory function in the C. elegans germ line, prp-8(rr40) may provide further insight into the etiology of this splicing-associated human disorder.",
          "offsetInBeginSection": 1520,
          "offsetInEndSection": 1725,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
          "text": "ulated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reacti",
          "offsetInBeginSection": 1305,
          "offsetInEndSection": 1455,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34348142",
        "http://www.ncbi.nlm.nih.gov/pubmed/23026070",
        "http://www.ncbi.nlm.nih.gov/pubmed/18945809",
        "http://www.ncbi.nlm.nih.gov/pubmed/7935475"
      ]
    },
    {
      "id": "641790d6690f196b5100002d",
      "type": "factoid",
      "body": "At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22115006",
          "text": "f corticosteroids slowed the loss of ambulation that develops in mid to late childhood. Corticosteroids, however, frequently produce unacceptable side",
          "offsetInBeginSection": 226,
          "offsetInEndSection": 376,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
          "text": "nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh",
          "offsetInBeginSection": 622,
          "offsetInEndSection": 772,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
          "text": "The impact of the disease presents as early as infancy with significant developmental delays, and ultimately loss of ambulation and respiratory insufficiency.",
          "offsetInBeginSection": 142,
          "offsetInEndSection": 300,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625891",
          "text": "wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 273,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
          "text": "Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12466073",
          "text": "Loss of independent gait occurred at similar ages in both groups (10.3 vs. 10.5 years).",
          "offsetInBeginSection": 971,
          "offsetInEndSection": 1058,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17388226",
          "text": "Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.",
          "offsetInBeginSection": 261,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25643053",
          "text": "ents with Duchenne muscular dystrophy aged 17.1 \u00b1 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 \u00b1 1",
          "offsetInBeginSection": 641,
          "offsetInEndSection": 791,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23440719",
          "text": "Glucocorticoid-treated patients who were IAAM homozygotes lost ambulation at 12.5 \u00b1 3.3 years compared to 10.7 \u00b1 2.1 years for treated VTTT heterozygotes or homozygotes.",
          "offsetInBeginSection": 787,
          "offsetInEndSection": 956,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
          "text": "Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s.",
          "offsetInBeginSection": 303,
          "offsetInEndSection": 414,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22115006",
        "http://www.ncbi.nlm.nih.gov/pubmed/21784636",
        "http://www.ncbi.nlm.nih.gov/pubmed/31588416",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625891",
        "http://www.ncbi.nlm.nih.gov/pubmed/12363102",
        "http://www.ncbi.nlm.nih.gov/pubmed/19834452",
        "http://www.ncbi.nlm.nih.gov/pubmed/23440719",
        "http://www.ncbi.nlm.nih.gov/pubmed/17388226",
        "http://www.ncbi.nlm.nih.gov/pubmed/12466073",
        "http://www.ncbi.nlm.nih.gov/pubmed/25643053"
      ]
    },
    {
      "id": "6404199d201352f04a000019",
      "type": "yesno",
      "body": "Is ocrelizumab effective for primary progressive multiple sclerosis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32920498",
          "text": "ary progressive multiple sclerosis (PPMS) with efficacy proven in a phase 3 randomised controlled trial. Eleven months prior to the European regulator",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "Conclusions: Our real-world study supports the tolerability, safety, and effectiveness of ocrelizumab in clinical practice.",
          "offsetInBeginSection": 1453,
          "offsetInEndSection": 1576,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
          "text": " remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and even",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
          "text": "of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ",
          "offsetInBeginSection": 1249,
          "offsetInEndSection": 1399,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35456175",
          "text": "In conclusion, our study highlighted that early ocrelizumab treatment is effective in modifying the disability accrual in MS patients.",
          "offsetInBeginSection": 2061,
          "offsetInEndSection": 2195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
          "text": "OBJECTIVES\nOcrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
          "text": "BACKGROUND\nOcrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
          "text": "lizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) ",
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32920498",
        "http://www.ncbi.nlm.nih.gov/pubmed/36454397",
        "http://www.ncbi.nlm.nih.gov/pubmed/33519676",
        "http://www.ncbi.nlm.nih.gov/pubmed/30160679",
        "http://www.ncbi.nlm.nih.gov/pubmed/33868559",
        "http://www.ncbi.nlm.nih.gov/pubmed/32777270",
        "http://www.ncbi.nlm.nih.gov/pubmed/35456175"
      ]
    },
    {
      "id": "641b7bba690f196b5100003e",
      "type": "summary",
      "body": "How is Indocyanine green (ICG) used?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
          "text": "s an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12140046",
          "text": "PURPOSE\nTo report an altered uptake and possible complication associated with the use of indocyanine green (ICG) dye, internal limiting membrane (ILM) peeling, and infrared diode laser.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
          "text": "We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
          "text": "Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
          "text": "Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels.",
          "offsetInBeginSection": 131,
          "offsetInEndSection": 237,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
          "text": "Systemic indocyanine green (ICG) clearance has been used to estimate splanchnic blood flow, but the results may be compromised by altered hepatic dye extraction.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35668312",
          "text": "Indocyanine green (ICG) is one of the methods used to assess vascularization, but this assessment is usually subjective.",
          "offsetInBeginSection": 152,
          "offsetInEndSection": 272,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35601636",
          "text": "ntly available in Korea. Indocyanine green (ICG) can be applied as an alternative agent. However, studies on colonoscopic tattooing by the direct inje",
          "offsetInBeginSection": 157,
          "offsetInEndSection": 307,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35662771",
          "text": "Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28316935",
        "http://www.ncbi.nlm.nih.gov/pubmed/33965600",
        "http://www.ncbi.nlm.nih.gov/pubmed/35601636",
        "http://www.ncbi.nlm.nih.gov/pubmed/7553712",
        "http://www.ncbi.nlm.nih.gov/pubmed/9018428",
        "http://www.ncbi.nlm.nih.gov/pubmed/35874138",
        "http://www.ncbi.nlm.nih.gov/pubmed/35668312",
        "http://www.ncbi.nlm.nih.gov/pubmed/12140046",
        "http://www.ncbi.nlm.nih.gov/pubmed/35662771"
      ]
    },
    {
      "id": "6428da74690f196b51000052",
      "type": "factoid",
      "body": "What is the process that generates multiple transcripts from the same gene?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
          "text": "Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
          "text": "Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30852095",
          "text": "Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20396891",
          "text": "We have shown earlier that this sunflower gene is interrupted by nine introns and generates multiple mRNAs by alternative splicing of its primary transcript (Lazarescu et al.",
          "offsetInBeginSection": 208,
          "offsetInEndSection": 382,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
          "text": "ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t",
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1508684",
          "text": "The chicken beta tropomyosin gene generates three major transcripts by alternative splicing.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 92,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968750",
          "text": "on can occur at multiple locations through a process known as alternative polyadenylation (APA). Therefore, APA is a form of co-transcriptional gene r",
          "offsetInBeginSection": 255,
          "offsetInEndSection": 405,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
          "text": "nt accordingly by regulating gene expression at multiple levels. Alternative splicing (AS), a widespread mechanism in eukaryotes that post-transcripti",
          "offsetInBeginSection": 80,
          "offsetInEndSection": 230,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
          "text": "Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 103,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34383135",
        "http://www.ncbi.nlm.nih.gov/pubmed/30852095",
        "http://www.ncbi.nlm.nih.gov/pubmed/29074233",
        "http://www.ncbi.nlm.nih.gov/pubmed/28402429",
        "http://www.ncbi.nlm.nih.gov/pubmed/22961303",
        "http://www.ncbi.nlm.nih.gov/pubmed/33793927",
        "http://www.ncbi.nlm.nih.gov/pubmed/20396891",
        "http://www.ncbi.nlm.nih.gov/pubmed/28968750",
        "http://www.ncbi.nlm.nih.gov/pubmed/29368663",
        "http://www.ncbi.nlm.nih.gov/pubmed/1508684"
      ]
    },
    {
      "id": "63f9cdcc33942b094c000013",
      "type": "yesno",
      "body": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
          "text": "Whether SRRM4 can also regulate a stem-cell gene network for NEPC development remains unclear.",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 531,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
          "text": "dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes. More importantly, this SRRM4-SOX",
          "offsetInBeginSection": 1553,
          "offsetInEndSection": 1703,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346347",
          "text": "quently occurs in cancer, but the mechanism and functional role of this silencing in oncogenesis are not fully understood. Here, we show that oncogeni",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27180064",
          "text": "ated adenocarcinoma cells to express NEPC biomarkers, and this effect was exacerbated by ARPI. ARPI combined with a gain of SRRM4-induced adenocarcino",
          "offsetInBeginSection": 1388,
          "offsetInEndSection": 1538,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27180064",
        "http://www.ncbi.nlm.nih.gov/pubmed/30100395",
        "http://www.ncbi.nlm.nih.gov/pubmed/27346347"
      ]
    },
    {
      "id": "64179aac690f196b51000037",
      "type": "factoid",
      "body": "What is the life expectancy for Duchenne muscular dystrophy patients?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
          "text": "eater Los Angeles area. Regardless of their ages, which ranged from 12 years to 21, the majority of the patients, as well as the majority of the paren",
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
          "text": "A total of 85 boys with Duchenne muscular dystrophy aged 8-18 years and 136 age, sex and living place matched healthy controls were included in this study.",
          "offsetInBeginSection": 159,
          "offsetInEndSection": 314,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
          "text": "tients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effect",
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19078632",
          "text": "ION\nLong-term steroid treatment in Duchenne muscular dystrophy (average. 65 mo) proved beneficial m terms of muscle strength, function, and tolerable ",
          "offsetInBeginSection": 1328,
          "offsetInEndSection": 1478,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
          "text": "lar dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines rega",
          "offsetInBeginSection": 27,
          "offsetInEndSection": 177,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34053847",
          "text": "As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity and mortality in these patients.",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
          "text": "and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g",
          "offsetInBeginSection": 45,
          "offsetInEndSection": 195,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
          "text": "RESULTS\nThe mean (SD) age was 26 (6) years and the mean age at which mechanical ventilation had initiated in the patients was 21 (5) years.",
          "offsetInBeginSection": 429,
          "offsetInEndSection": 568,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
          "text": "RESULTS\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 885,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/10193393",
        "http://www.ncbi.nlm.nih.gov/pubmed/19078632",
        "http://www.ncbi.nlm.nih.gov/pubmed/28099279",
        "http://www.ncbi.nlm.nih.gov/pubmed/33075081",
        "http://www.ncbi.nlm.nih.gov/pubmed/17939910",
        "http://www.ncbi.nlm.nih.gov/pubmed/27234309",
        "http://www.ncbi.nlm.nih.gov/pubmed/6696607",
        "http://www.ncbi.nlm.nih.gov/pubmed/33012180",
        "http://www.ncbi.nlm.nih.gov/pubmed/34053847"
      ]
    },
    {
      "id": "64041e97201352f04a00001e",
      "type": "yesno",
      "body": "Is daridorexant effective for insomnia?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
          "text": "BACKGROUND\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": "were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\u2009=\u20091.19; 95% ",
          "offsetInBeginSection": 861,
          "offsetInEndSection": 1011,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
          "text": "OBJECTIVE\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
          "text": "in the two placebo-controlled phase III trials that evaluated the efficacy and safety of daridorexant. The DCE design was informed by a two-phase qual",
          "offsetInBeginSection": 279,
          "offsetInEndSection": 429,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
          "text": "e events were nasopharyngitis and headache.\n\n\nCONCLUSION\nDaridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1086,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36309969",
          "text": "Morning administration is not relevant for daridorexant use by insomnia patients.",
          "offsetInBeginSection": 1246,
          "offsetInEndSection": 1327,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": " p=0\u00b7012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for",
          "offsetInBeginSection": 4108,
          "offsetInEndSection": 4258,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
          "text": "th 1; -1\u00b70 [-2\u00b70 to 0\u00b701], p=0\u00b7053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared",
          "offsetInBeginSection": 3306,
          "offsetInEndSection": 3456,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
          "text": " (RR\u2009=\u20092.01; 95% CI, 1.21-3.36; P\u2009=\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly h",
          "offsetInBeginSection": 1116,
          "offsetInEndSection": 1266,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
          "text": "Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.",
          "offsetInBeginSection": 1528,
          "offsetInEndSection": 1629,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
        "http://www.ncbi.nlm.nih.gov/pubmed/36054921",
        "http://www.ncbi.nlm.nih.gov/pubmed/32341187",
        "http://www.ncbi.nlm.nih.gov/pubmed/36309969",
        "http://www.ncbi.nlm.nih.gov/pubmed/36098753",
        "http://www.ncbi.nlm.nih.gov/pubmed/34331678",
        "http://www.ncbi.nlm.nih.gov/pubmed/35065036",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030"
      ]
    },
    {
      "id": "6422ee03690f196b51000046",
      "type": "factoid",
      "body": "What cells produce erythroferrone?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31723763",
          "text": "Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.",
          "offsetInBeginSection": 825,
          "offsetInEndSection": 1012,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30097509",
          "text": "Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 274,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
          "text": "Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
          "text": "Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
          "text": "pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress",
          "offsetInBeginSection": 305,
          "offsetInEndSection": 455,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
          "text": "Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.",
          "offsetInBeginSection": 1033,
          "offsetInEndSection": 1239,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
          "text": "Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.",
          "offsetInBeginSection": 894,
          "offsetInEndSection": 1129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31846624",
          "text": " blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ",
          "offsetInBeginSection": 624,
          "offsetInEndSection": 774,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27161430",
          "text": "ency, hypoxia and EPO treatment. Erythroferrone, produced by EPO-stimulated erythropoiesis, inhibits hepcidin only when the activity of BMP/SMAD pathw",
          "offsetInBeginSection": 1315,
          "offsetInEndSection": 1465,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
          "text": "Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.",
          "offsetInBeginSection": 494,
          "offsetInEndSection": 621,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35628152",
        "http://www.ncbi.nlm.nih.gov/pubmed/35464433",
        "http://www.ncbi.nlm.nih.gov/pubmed/31808893",
        "http://www.ncbi.nlm.nih.gov/pubmed/30097509",
        "http://www.ncbi.nlm.nih.gov/pubmed/28629515",
        "http://www.ncbi.nlm.nih.gov/pubmed/28739636",
        "http://www.ncbi.nlm.nih.gov/pubmed/27161430",
        "http://www.ncbi.nlm.nih.gov/pubmed/31846624",
        "http://www.ncbi.nlm.nih.gov/pubmed/24880340",
        "http://www.ncbi.nlm.nih.gov/pubmed/31723763"
      ]
    },
    {
      "id": "6429f86657b1c7a31500000d",
      "type": "summary",
      "body": "What is the role of the Mediator in gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
          "text": "Therefore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for C. elegans development.",
          "offsetInBeginSection": 771,
          "offsetInEndSection": 948,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
          "text": "The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16885160",
          "text": "ChREBP and Mlx dimerize and function together as a glucose-responsive transcription factor to regulate target genes, such as liver-type pyruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase.",
          "offsetInBeginSection": 204,
          "offsetInEndSection": 407,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21854862",
        "http://www.ncbi.nlm.nih.gov/pubmed/10611325",
        "http://www.ncbi.nlm.nih.gov/pubmed/16885160"
      ]
    },
    {
      "id": "6415c0df690f196b51000010",
      "type": "factoid",
      "body": "What does FBDD stand for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23410157",
          "text": " the chances of identifying active molecules. Among them, the Fragment Based Drug Design (FBDD) is surely worth noting. The FBDD entails the screening",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345344",
          "text": "In the last decade, fragment-based drug discovery (FBDD) has evolved from a novel approach in the search of new hits to a valuable alternative to the high-throughput screening (HTS) campaigns of many pharmaceutical companies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
          "text": "Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
          "text": "Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36044560",
          "text": "The technique of Fragment-Based Drug Design (FBDD) considers the interactions of different moieties of molecules with biological targets for the rational construction of potential drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
          "text": "Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
          "text": "Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21482811",
          "text": "Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32133344",
          "text": "Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
          "text": "Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25420726",
        "http://www.ncbi.nlm.nih.gov/pubmed/23410157",
        "http://www.ncbi.nlm.nih.gov/pubmed/32339336",
        "http://www.ncbi.nlm.nih.gov/pubmed/36044560",
        "http://www.ncbi.nlm.nih.gov/pubmed/32850968",
        "http://www.ncbi.nlm.nih.gov/pubmed/21482811",
        "http://www.ncbi.nlm.nih.gov/pubmed/20345344",
        "http://www.ncbi.nlm.nih.gov/pubmed/22459076",
        "http://www.ncbi.nlm.nih.gov/pubmed/34348623",
        "http://www.ncbi.nlm.nih.gov/pubmed/32133344"
      ]
    },
    {
      "id": "64041dae201352f04a00001d",
      "type": "yesno",
      "body": "Is deucravacitinib effective for psoriasis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
          "text": "The latest IL-17 and IL-23 inhibitors include bimekizumab, netakimab and mirikizumab as well as oral small molecules, such as deucravacitinib, a tyrosine kinase 2 selective inhibitor, and piclidenoson, an agonist of the Gi protein-associated A3 adenosine receptor.",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1524,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
          "text": " (OR 1.6 [95% CI 0.8, 2.9]; nominal P\u00a0=\u00a00.08 versus placebo). Response rates were higher with deucravacitinib treatment for BICLA, CLASI-50, LLDAS, an",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36115523",
          "text": "vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w",
          "offsetInBeginSection": 832,
          "offsetInEndSection": 982,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": " oral psoriasis treatments are needed.\n\n\nOBJECTIVE\nTo compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibit",
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
          "text": "so reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromb",
          "offsetInBeginSection": 1115,
          "offsetInEndSection": 1265,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
          "text": "Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast.",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 710,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
          "text": "OBJECTIVE\nTo evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
          "text": "of deucravacitinib versus lower doses or placebo.\n\n\nCONCLUSION\nRobust clinical efficacy with deucravacitinib treatment was associated with decreases i",
          "offsetInBeginSection": 1563,
          "offsetInEndSection": 1713,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
          "text": "CONCLUSION\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.",
          "offsetInBeginSection": 1191,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36469536",
        "http://www.ncbi.nlm.nih.gov/pubmed/34239295",
        "http://www.ncbi.nlm.nih.gov/pubmed/36369798",
        "http://www.ncbi.nlm.nih.gov/pubmed/35820547",
        "http://www.ncbi.nlm.nih.gov/pubmed/34767869",
        "http://www.ncbi.nlm.nih.gov/pubmed/35241426",
        "http://www.ncbi.nlm.nih.gov/pubmed/35960487",
        "http://www.ncbi.nlm.nih.gov/pubmed/36115523"
      ]
    },
    {
      "id": "6415b6eb690f196b5100000b",
      "type": "list",
      "body": "What processes do orexin/hypocretin neurons regulate?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32314734",
          "text": "e in the hypothalamus and project throughout the brain to regulate sleep/wakefulness. Ablation of orexin neurons decreases wakefulness and results in ",
          "offsetInBeginSection": 101,
          "offsetInEndSection": 251,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
          "text": "However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.",
          "offsetInBeginSection": 233,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12106679",
          "text": "ypothalamic orexin/hypocretin-containing neurons in the control of sleep-wakefulness. To help determine if adenosine might play a role in the control ",
          "offsetInBeginSection": 122,
          "offsetInEndSection": 272,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16731510",
          "text": "ote wakefulness (their loss causes narcolepsy) and also regulate metabolism and reward. Here we demonstrate that their inhibition by glucose is mediat",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 364,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
          "text": " have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil",
          "offsetInBeginSection": 64,
          "offsetInEndSection": 214,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
          "text": "is a critical regulator of physiological processes including sleep/wakefulness and feeding. Using organotypic slice culture of rat hypothalamus, we fo",
          "offsetInBeginSection": 48,
          "offsetInEndSection": 198,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12495630",
          "text": "Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
          "text": "hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp",
          "offsetInBeginSection": 437,
          "offsetInEndSection": 587,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12495630",
        "http://www.ncbi.nlm.nih.gov/pubmed/34052808",
        "http://www.ncbi.nlm.nih.gov/pubmed/22813966",
        "http://www.ncbi.nlm.nih.gov/pubmed/16054072",
        "http://www.ncbi.nlm.nih.gov/pubmed/32314734",
        "http://www.ncbi.nlm.nih.gov/pubmed/12106679",
        "http://www.ncbi.nlm.nih.gov/pubmed/20307612",
        "http://www.ncbi.nlm.nih.gov/pubmed/16731510"
      ]
    },
    {
      "id": "6428da47690f196b51000051",
      "type": "yesno",
      "body": "Can the epigenetic status of introns affect gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
          "text": "However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.",
          "offsetInBeginSection": 86,
          "offsetInEndSection": 212,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213601",
          "text": "Epigenetic modifications affect gene expression and thereby govern a wide range of biological processes such as differentiation, development and tumorigenesis.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
          "text": "n, and their contributions to genetic diversity and evolution, remain poorly understood. In this study, we investigated the genome-wide distribution o",
          "offsetInBeginSection": 369,
          "offsetInEndSection": 519,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
          "text": "and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression. The nucleosome formation potential is al",
          "offsetInBeginSection": 66,
          "offsetInEndSection": 216,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34823400",
          "text": "Epigenetic modifications can affect gene expression and function and can also mediate crosstalk between genes and the environment.",
          "offsetInBeginSection": 264,
          "offsetInEndSection": 394,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24737381",
          "text": "We conclude that alterations in the methylation status of protein-coding genes and various miRNA genes are influenced by HPV infection, the viral genotype, the physical state of the viral DNA, and viral oncogenic risk.",
          "offsetInBeginSection": 829,
          "offsetInEndSection": 1047,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
          "text": "Introns can increase gene expression levels using a variety of mechanisms collectively referred to as Intron Mediated Enhancement (IME).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
          "text": "Introns exist in the transcribed DNA and the nascent RNA, and could affect expression from either location.",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
          "text": "Epigenetic modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18287520",
          "text": "However, in yeast only 283 of the 6000 genes contain introns and their impact on cell function is not clear.",
          "offsetInBeginSection": 96,
          "offsetInEndSection": 204,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18319396",
        "http://www.ncbi.nlm.nih.gov/pubmed/32187179",
        "http://www.ncbi.nlm.nih.gov/pubmed/34823400",
        "http://www.ncbi.nlm.nih.gov/pubmed/22645558",
        "http://www.ncbi.nlm.nih.gov/pubmed/31235724",
        "http://www.ncbi.nlm.nih.gov/pubmed/24737381",
        "http://www.ncbi.nlm.nih.gov/pubmed/24213601",
        "http://www.ncbi.nlm.nih.gov/pubmed/24455281",
        "http://www.ncbi.nlm.nih.gov/pubmed/15673716",
        "http://www.ncbi.nlm.nih.gov/pubmed/18287520"
      ]
    },
    {
      "id": "6415c5d4690f196b51000014",
      "type": "list",
      "body": "What was Keytruda originally approved for by the FDA?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
          "text": "ons in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-ce",
          "offsetInBeginSection": 318,
          "offsetInEndSection": 468,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
          "text": " Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ",
          "offsetInBeginSection": 218,
          "offsetInEndSection": 368,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
          "text": "rug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in s",
          "offsetInBeginSection": 1937,
          "offsetInEndSection": 2087,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34156377",
          "text": "Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
          "text": "Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates.",
          "offsetInBeginSection": 685,
          "offsetInEndSection": 1133,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3477937",
          "text": "Two of the EWCL brands were approved by the United States Food and Drug Administration (FDA) for wear by the public, while two of the brands were uninvestigated.",
          "offsetInBeginSection": 145,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26429199",
          "text": "A total of 130 FDA-approved drugs, originally intended against other diseases, could be repurposed against 78 potential targets in M. tuberculosis.",
          "offsetInBeginSection": 712,
          "offsetInEndSection": 859,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
          "text": "The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
          "text": "The fact that this IUD is approved for 6 years makes it an even more attractive option for women choosing a contraceptive method.\"",
          "offsetInBeginSection": 1104,
          "offsetInEndSection": 1234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
          "text": "On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 345,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28235882",
        "http://www.ncbi.nlm.nih.gov/pubmed/26429199",
        "http://www.ncbi.nlm.nih.gov/pubmed/32645193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28835513",
        "http://www.ncbi.nlm.nih.gov/pubmed/12179363",
        "http://www.ncbi.nlm.nih.gov/pubmed/17280539",
        "http://www.ncbi.nlm.nih.gov/pubmed/29209918",
        "http://www.ncbi.nlm.nih.gov/pubmed/34647523",
        "http://www.ncbi.nlm.nih.gov/pubmed/3477937",
        "http://www.ncbi.nlm.nih.gov/pubmed/34156377"
      ]
    },
    {
      "id": "63f5713733942b094c000003",
      "type": "summary",
      "body": "What are clinical features of the Achard-Thiers syndrome?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
          "text": "The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 120,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/518037",
          "text": "The clinical and neuroradiological features in 4 patients with the syndrome of aberrant regeneration of the third nerve are presented.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8166424",
          "text": "ions in two of the boys, confirmed diagnosis. The clinical, hematological and radiological features are discussed in order to better define what appea",
          "offsetInBeginSection": 330,
          "offsetInEndSection": 480,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
          "text": "ile other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume. The term C",
          "offsetInBeginSection": 1260,
          "offsetInEndSection": 1410,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
          "text": "What determines the various clinical and imaging features of this syndrome seems to be the loss of CSF volume as the independent variable, while other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume.",
          "offsetInBeginSection": 1119,
          "offsetInEndSection": 1399,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695356",
          "text": "METHODS\nThe following clinical and MRI findings were assessed: age, gender, pain, pain attributable to lesion, tumour location, tumour length, presence, depth of endosteal scalloping, bone marrow oedema, soft tissue oedema, cortical destruction, periosteal reaction, bone expansion, macroscopic fat, calcification, soft tissue mass, haemorrhage, dynamic contrast-enhanced MRI.",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 548,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24173296",
          "text": "Obesity, hypertension and angiopathy were present in most of these patients.",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 239,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1201353",
        "http://www.ncbi.nlm.nih.gov/pubmed/8166424",
        "http://www.ncbi.nlm.nih.gov/pubmed/10560599",
        "http://www.ncbi.nlm.nih.gov/pubmed/24173296",
        "http://www.ncbi.nlm.nih.gov/pubmed/518037",
        "http://www.ncbi.nlm.nih.gov/pubmed/28695356"
      ]
    },
    {
      "id": "642d4c9b57b1c7a315000013",
      "type": "yesno",
      "body": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?",
      "snippets": [],
      "documents": []
    },
    {
      "id": "6429fe4e57b1c7a31500000f",
      "type": "summary",
      "body": "What are coactivators?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
          "text": "ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ",
          "offsetInBeginSection": 879,
          "offsetInEndSection": 1029,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19843848",
          "text": "Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9096323",
          "text": "uld be rescued from E1A inhibition by overexpression of CBP or p300. CBP and p300 act as coactivators of p65-driven gene activation and may play an im",
          "offsetInBeginSection": 909,
          "offsetInEndSection": 1059,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10379889",
          "text": "In fact, squelching becomes even more severe when coactivators are abundant.",
          "offsetInBeginSection": 1084,
          "offsetInEndSection": 1160,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11893487",
          "text": "Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
          "text": "development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init",
          "offsetInBeginSection": 70,
          "offsetInEndSection": 220,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
          "text": "ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ",
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1338,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
          "text": "160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans",
          "offsetInBeginSection": 413,
          "offsetInEndSection": 563,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
          "text": "Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
          "text": "relevant brain regions coexpress nuclear receptor coactivators and steroid receptors. Confocal analysis revealed that in oestrogen-primed rats, most o",
          "offsetInBeginSection": 1159,
          "offsetInEndSection": 1309,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17244199",
        "http://www.ncbi.nlm.nih.gov/pubmed/12376547",
        "http://www.ncbi.nlm.nih.gov/pubmed/10379889",
        "http://www.ncbi.nlm.nih.gov/pubmed/9096323",
        "http://www.ncbi.nlm.nih.gov/pubmed/26201947",
        "http://www.ncbi.nlm.nih.gov/pubmed/9806345",
        "http://www.ncbi.nlm.nih.gov/pubmed/17476305",
        "http://www.ncbi.nlm.nih.gov/pubmed/19843848",
        "http://www.ncbi.nlm.nih.gov/pubmed/14690606",
        "http://www.ncbi.nlm.nih.gov/pubmed/11893487"
      ]
    },
    {
      "id": "6412331b201352f04a000038",
      "type": "factoid",
      "body": "What are PROTACs?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31873151",
          "text": "Proteolysis targeting chimeras (PROTACs) are an emerging strategy for promoting targeted protein degradation by inducing the proximity between targeted proteins and E3 ubiquitin ligases.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34175722",
          "text": "Proteolysis targeting chimeras (PROTACs) have been developed to be an effective technology for targeted protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494353",
          "text": "Proteolysis-targeting chimeras (PROTACs), an emerging paradigm-shifting technology, hijacks the ubiquitin-proteasome system for targeted protein degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
          "text": "Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15876533",
          "text": "PROTACS are small molecule chimera which comprise a ligand and a peptide recognition motif for an E3 ligase.",
          "offsetInBeginSection": 130,
          "offsetInEndSection": 238,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32475992",
          "text": " as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interes",
          "offsetInBeginSection": 115,
          "offsetInEndSection": 265,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
          "text": "Proteolysis-targeting chimeras (PROTACs), bifunctional molecules consisting of a ligand of protein of interest (POI), an E3 ligase ligand and a linker, have been developed to hijack the ubiquitin-proteasome system (UPS) to induce different POIs degradation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35001407",
          "text": "Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
          "text": "Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs) is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relatively high molecular weight.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 264,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
          "text": "h the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a li",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34175722",
        "http://www.ncbi.nlm.nih.gov/pubmed/35916511",
        "http://www.ncbi.nlm.nih.gov/pubmed/34494353",
        "http://www.ncbi.nlm.nih.gov/pubmed/15876533",
        "http://www.ncbi.nlm.nih.gov/pubmed/32475992",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533582",
        "http://www.ncbi.nlm.nih.gov/pubmed/31538491",
        "http://www.ncbi.nlm.nih.gov/pubmed/35001407",
        "http://www.ncbi.nlm.nih.gov/pubmed/34034148",
        "http://www.ncbi.nlm.nih.gov/pubmed/31873151"
      ]
    },
    {
      "id": "62008022c9dfcb9c0900001b",
      "type": "list",
      "body": "Which variables are included in the ALBI grade?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026834",
          "text": "A newly developed scoring system called albumin-bilirubin grade (ALBI grade), consists of albumin and bilirubin to assess liver function reserve objectively.",
          "offsetInBeginSection": 253,
          "offsetInEndSection": 410,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
          "text": "RESULTS\nALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type.",
          "offsetInBeginSection": 556,
          "offsetInEndSection": 676,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30077606",
          "text": "The albumin-bilirubin (ALBI) grade, a measure of liver function based on albumin and bilirubin, has the potential to detect Child-Pugh grade A HCC patients with poor prognosis.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 331,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies.",
          "offsetInBeginSection": 2136,
          "offsetInEndSection": 2359,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
          "text": "Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.",
          "offsetInBeginSection": 497,
          "offsetInEndSection": 612,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
          "text": "Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades.",
          "offsetInBeginSection": 734,
          "offsetInEndSection": 825,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392490",
          "text": "BACKGROUND & AIMS\nThe albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
          "text": "Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.",
          "offsetInBeginSection": 1048,
          "offsetInEndSection": 1202,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26462681",
          "text": "METHODS\nWe evaluated the correlations between the ALBI grade and Child-Pugh score, adverse events, and survival in 89 patients with advanced HCC who were prospectively treated with sorafenib.",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 432,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
          "text": "BACKGROUND\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 169,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36411535",
        "http://www.ncbi.nlm.nih.gov/pubmed/28688815",
        "http://www.ncbi.nlm.nih.gov/pubmed/30026834",
        "http://www.ncbi.nlm.nih.gov/pubmed/32411593",
        "http://www.ncbi.nlm.nih.gov/pubmed/31191834",
        "http://www.ncbi.nlm.nih.gov/pubmed/33788758",
        "http://www.ncbi.nlm.nih.gov/pubmed/26462681",
        "http://www.ncbi.nlm.nih.gov/pubmed/30077606",
        "http://www.ncbi.nlm.nih.gov/pubmed/33392490"
      ]
    },
    {
      "id": "64240f33690f196b51000049",
      "type": "list",
      "body": "What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
          "text": "fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a",
          "offsetInBeginSection": 52,
          "offsetInEndSection": 202,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
          "text": "ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/793459",
          "text": "Serum antibodies to the feline infectious peritonitis (FIP) virus were measured in cats, using an indirect fluorescent antibody procedure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 138,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31375588",
          "text": "Our recombinant FCoVs are powerful tools for increasing our understanding of the viral life cycle and pathogenesis of FIP-inducing type I FCoV.IMPORTANCE Feline coronavirus (FCoV) is one of the most significant coronaviruses, because this virus induces feline infectious peritonitis (FIP), which is a lethal disease in cats.",
          "offsetInBeginSection": 1498,
          "offsetInEndSection": 1822,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002137",
          "text": "Research has demonstrated efficacy of new antivirals in FIP treatment, but these products are not legally available in many countries at this time.",
          "offsetInBeginSection": 1694,
          "offsetInEndSection": 1841,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36387398",
          "text": "ive and no relapse was observed.\n\n\nConclusions and relevance\nGS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces",
          "offsetInBeginSection": 1427,
          "offsetInEndSection": 1577,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19058829",
          "text": "The lethal pathology associated with FIP (granulomatous inflammation and T-cell lymphopenia) is thought to be mediated by aberrant modulation of the immune system due to infection of cells such as monocytes and macrophages.",
          "offsetInBeginSection": 188,
          "offsetInEndSection": 411,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
          "text": "ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
          "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.",
          "offsetInBeginSection": 620,
          "offsetInEndSection": 736,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20180212",
          "text": "Current treatments are crude and involve supportive care and immunosuppression.",
          "offsetInBeginSection": 439,
          "offsetInEndSection": 518,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19058829",
        "http://www.ncbi.nlm.nih.gov/pubmed/19482534",
        "http://www.ncbi.nlm.nih.gov/pubmed/793459",
        "http://www.ncbi.nlm.nih.gov/pubmed/36002137",
        "http://www.ncbi.nlm.nih.gov/pubmed/18196725",
        "http://www.ncbi.nlm.nih.gov/pubmed/33799985",
        "http://www.ncbi.nlm.nih.gov/pubmed/31375588",
        "http://www.ncbi.nlm.nih.gov/pubmed/15123155",
        "http://www.ncbi.nlm.nih.gov/pubmed/20180212",
        "http://www.ncbi.nlm.nih.gov/pubmed/36387398"
      ]
    },
    {
      "id": "6428da98690f196b51000053",
      "type": "yesno",
      "body": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32511488",
          "text": "Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
          "text": "million cases have occurred worldwide as of June 16, 2020. However, it is important to distinguish COVID-19 from other respiratory infectious diseases",
          "offsetInBeginSection": 88,
          "offsetInEndSection": 238,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
          "text": " hospitalized patients with other viral pneumonias such as influenza is unknown.\n\n\nObjectives\nTo assess the incidence of venous and arterial thromboti",
          "offsetInBeginSection": 327,
          "offsetInEndSection": 477,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
          "text": "n most\u00a0other contagious respiratory illnesses. The\u00a0mechanisms underlying this difference remain unclear.\n\n\nMETHODS\nWe compared the immunological lands",
          "offsetInBeginSection": 79,
          "offsetInEndSection": 229,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32832306",
          "text": "COVID-19) are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 pandemic is caused by a novel virus - severe a",
          "offsetInBeginSection": 40,
          "offsetInEndSection": 190,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
          "text": "Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 306,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
          "text": "Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.",
          "offsetInBeginSection": 214,
          "offsetInEndSection": 404,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
          "text": "ose with dengue or influenza, adjusting for age, subregion, and days from illness onset to presentation for clinical care. Among 13,431 participants, ",
          "offsetInBeginSection": 697,
          "offsetInEndSection": 847,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
          "text": "other respiratory viral infections, such as Influenza, has not hitherto been extensively studied. We aimed to compare the prognostic value of NLR in C",
          "offsetInBeginSection": 163,
          "offsetInEndSection": 313,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34484383",
          "text": "CONCLUSION\nDuring influenza season, differentiating other causes of respiratory illness from COVID-19 is difficult, because common clinical manifestations of COVID-19 mimic those of influenza.",
          "offsetInBeginSection": 694,
          "offsetInEndSection": 886,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36410319",
        "http://www.ncbi.nlm.nih.gov/pubmed/34111501",
        "http://www.ncbi.nlm.nih.gov/pubmed/34728719",
        "http://www.ncbi.nlm.nih.gov/pubmed/32511488",
        "http://www.ncbi.nlm.nih.gov/pubmed/33947345",
        "http://www.ncbi.nlm.nih.gov/pubmed/33090987",
        "http://www.ncbi.nlm.nih.gov/pubmed/34484383",
        "http://www.ncbi.nlm.nih.gov/pubmed/33907612",
        "http://www.ncbi.nlm.nih.gov/pubmed/33821230",
        "http://www.ncbi.nlm.nih.gov/pubmed/32832306"
      ]
    },
    {
      "id": "6415c8f1690f196b51000017",
      "type": "factoid",
      "body": "Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
          "text": "used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have b",
          "offsetInBeginSection": 92,
          "offsetInEndSection": 242,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18420499",
          "text": "xel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer.\n\n\nMETHODS\nWe enrolled 4950 women with axillary lymph node-posit",
          "offsetInBeginSection": 83,
          "offsetInEndSection": 233,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "rubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast cancer. In addition to standard eligibility criteria, patients with c",
          "offsetInBeginSection": 169,
          "offsetInEndSection": 319,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
          "text": "her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici",
          "offsetInBeginSection": 90,
          "offsetInEndSection": 240,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
          "text": "While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.",
          "offsetInBeginSection": 1324,
          "offsetInEndSection": 1611,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
          "text": "apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
          "text": "re among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall",
          "offsetInBeginSection": 106,
          "offsetInEndSection": 256,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11129728",
          "text": "The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
          "text": "We conclude that the combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activity.",
          "offsetInBeginSection": 1939,
          "offsetInEndSection": 2111,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11432615",
          "text": "BACKGROUND\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26918039",
        "http://www.ncbi.nlm.nih.gov/pubmed/10426454",
        "http://www.ncbi.nlm.nih.gov/pubmed/9865708",
        "http://www.ncbi.nlm.nih.gov/pubmed/11552225",
        "http://www.ncbi.nlm.nih.gov/pubmed/8629032",
        "http://www.ncbi.nlm.nih.gov/pubmed/11129728",
        "http://www.ncbi.nlm.nih.gov/pubmed/18420499",
        "http://www.ncbi.nlm.nih.gov/pubmed/12473512",
        "http://www.ncbi.nlm.nih.gov/pubmed/11432615"
      ]
    },
    {
      "id": "63eeec79f36125a426000006",
      "type": "factoid",
      "body": "Talquetamab was developed for treatment of which disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
          "text": "cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 231,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
          "text": "OBJECTIVES\nThe objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing s",
          "offsetInBeginSection": 1620,
          "offsetInEndSection": 1770,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
          "text": "CASE REPORT\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.",
          "offsetInBeginSection": 451,
          "offsetInEndSection": 715,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25949982",
          "text": "ocrinology unit with excessive sweating. We started methimazole for Graves' disease. Without any additional immunosuppressive treatment, at week 12 of",
          "offsetInBeginSection": 95,
          "offsetInEndSection": 245,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
          "text": "In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.",
          "offsetInBeginSection": 920,
          "offsetInEndSection": 1011,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26193648",
          "text": "It was indicated that danaparoid sodium was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.",
          "offsetInBeginSection": 887,
          "offsetInEndSection": 1074,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
          "text": "Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
          "text": "as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of pa",
          "offsetInBeginSection": 58,
          "offsetInEndSection": 208,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36464766",
        "http://www.ncbi.nlm.nih.gov/pubmed/8100702",
        "http://www.ncbi.nlm.nih.gov/pubmed/25949982",
        "http://www.ncbi.nlm.nih.gov/pubmed/33890981",
        "http://www.ncbi.nlm.nih.gov/pubmed/12772593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36006441",
        "http://www.ncbi.nlm.nih.gov/pubmed/11449698",
        "http://www.ncbi.nlm.nih.gov/pubmed/26193648"
      ]
    },
    {
      "id": "642321a5690f196b51000047",
      "type": "summary",
      "body": "Please summarize Feline Spongiform Encephalopathy(FSE",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11206004",
          "text": "Feline Spongiform Encephalopathy (FSE) is a related disorder in domestic cats.",
          "offsetInBeginSection": 199,
          "offsetInEndSection": 277,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783238",
          "text": "Here we report an immunohistological analysis of the first FSE-affected cheetah born in France.",
          "offsetInBeginSection": 168,
          "offsetInEndSection": 263,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10349202",
          "text": "This review summarizes current knowledge of prion diseases and investigates connections between the bovine spongiform encephalopathy epidemic, observed in Great Britain since 1986, and the new variant of human Creutzfeldt-Jakob disease, reported for the first time in 1996.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 273,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19335885",
          "text": "BACKGROUND\nTwo domestic shorthair cats presenting with progressive hind-limb ataxia and increased aggressiveness were necropsied and a post mortem diagnosis of Feline Spongiform Encephalopathy (FSE) was made.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
          "text": "Feline spongiform encephalopathy was confirmed by histological brain examination and positive immunohistochemistry for PrPSc.",
          "offsetInBeginSection": 514,
          "offsetInEndSection": 639,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1279883",
          "text": "Thirteen cats were referred with clinical neurological signs potentially indicative of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 161,
          "offsetInEndSection": 287,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35632724",
          "text": "To the best of our knowledge, this is the first report on genetic polymorphisms of the feline SPRN gene.",
          "offsetInBeginSection": 2047,
          "offsetInEndSection": 2151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
          "text": "Clinically, it presents as a progressive fatal neurologic syndrome that is not easily distinguished from other feline neurologic conditions.",
          "offsetInBeginSection": 332,
          "offsetInEndSection": 472,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33374431",
          "text": "However, to date, investigations of PRNP polymorphisms are rare in cats, which are the major host of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 284,
          "offsetInEndSection": 424,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35632724",
          "text": "However, genetic polymorphisms in the feline SPRN gene and structural characteristics of the Sho have not been investigated in cats, a major host of feline spongiform encephalopathy (FSE).",
          "offsetInBeginSection": 506,
          "offsetInEndSection": 694,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12783238",
        "http://www.ncbi.nlm.nih.gov/pubmed/33374431",
        "http://www.ncbi.nlm.nih.gov/pubmed/1279883",
        "http://www.ncbi.nlm.nih.gov/pubmed/18725465",
        "http://www.ncbi.nlm.nih.gov/pubmed/19335885",
        "http://www.ncbi.nlm.nih.gov/pubmed/11206004",
        "http://www.ncbi.nlm.nih.gov/pubmed/12442705",
        "http://www.ncbi.nlm.nih.gov/pubmed/10349202",
        "http://www.ncbi.nlm.nih.gov/pubmed/35632724"
      ]
    },
    {
      "id": "6428d7da690f196b51000050",
      "type": "yesno",
      "body": "Can untranslated regions (UTRs) regulate gene expression?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
          "text": " (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 346,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21187351",
          "text": " regions (UTRs) of messenger RNAs. However, how the target sites change during evolution is largely unknown. MiR-iab-4 and miR-iab-4as are known to re",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 333,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23949786",
          "text": "However, the functions of the segment-specific regions of the UTRs are not well known.",
          "offsetInBeginSection": 210,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
          "text": "Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
          "text": "5' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
          "text": "3' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
          "text": "n of gene expression; however, the exact sequence features contributing to gene regulation are not yet fully understood. In this study, we report the ",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29223924",
          "text": "To facilitate this activation, plant mRNA contains untranslated regions (UTRs) that significantly increase the coding capacity of the genome by producing multiple mRNA variants from the same gene.",
          "offsetInBeginSection": 191,
          "offsetInEndSection": 387,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
          "text": "The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability.",
          "offsetInBeginSection": 183,
          "offsetInEndSection": 347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
          "text": "Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29223924",
        "http://www.ncbi.nlm.nih.gov/pubmed/31234415",
        "http://www.ncbi.nlm.nih.gov/pubmed/21912852",
        "http://www.ncbi.nlm.nih.gov/pubmed/20563548",
        "http://www.ncbi.nlm.nih.gov/pubmed/18615019",
        "http://www.ncbi.nlm.nih.gov/pubmed/8813126",
        "http://www.ncbi.nlm.nih.gov/pubmed/21093468",
        "http://www.ncbi.nlm.nih.gov/pubmed/23949786",
        "http://www.ncbi.nlm.nih.gov/pubmed/32995550",
        "http://www.ncbi.nlm.nih.gov/pubmed/21187351"
      ]
    },
    {
      "id": "63f9cbb433942b094c00000c",
      "type": "yesno",
      "body": "Is alternative splicing associated with heart disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049307",
          "text": "and 5 of the cTnT gene. Alternative splicing of cTnT exon 5 is developmentally regulated. cTnT isoforms containing exon 5 are expressed in the fetal a",
          "offsetInBeginSection": 109,
          "offsetInEndSection": 259,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
          "text": "assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va",
          "offsetInBeginSection": 753,
          "offsetInEndSection": 903,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25685889",
          "text": ",333 cis sQTLs involving 2,650 unique genes. Many sQTL-associated genes (40%) undergo alternative splicing. Using the National Human Genome Research I",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 578,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15652472",
          "text": "(2005) demonstrate that a heart-specific knockout of one SR protein, ASF/SF2, produces cardiomyopathy and misregulation of specific alternative splicing events during early postnatal development.",
          "offsetInBeginSection": 170,
          "offsetInEndSection": 365,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
          "text": "In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.",
          "offsetInBeginSection": 904,
          "offsetInEndSection": 1256,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
          "text": "Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.",
          "offsetInBeginSection": 757,
          "offsetInEndSection": 977,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561820",
          "text": " from individual genes; however, aberrant mRNA splicing is associated with various conditions, including heart disease. A recent study provides new me",
          "offsetInBeginSection": 76,
          "offsetInEndSection": 226,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358217",
          "text": "Alternative splicing could play a role in the control of gene expression during CKD but it does not seem to be a major mechanism.",
          "offsetInBeginSection": 1578,
          "offsetInEndSection": 1707,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
          "text": "e been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about ",
          "offsetInBeginSection": 213,
          "offsetInEndSection": 363,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15652472",
        "http://www.ncbi.nlm.nih.gov/pubmed/27049307",
        "http://www.ncbi.nlm.nih.gov/pubmed/30051286",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938400",
        "http://www.ncbi.nlm.nih.gov/pubmed/30468920",
        "http://www.ncbi.nlm.nih.gov/pubmed/25685889",
        "http://www.ncbi.nlm.nih.gov/pubmed/24358217",
        "http://www.ncbi.nlm.nih.gov/pubmed/32276354",
        "http://www.ncbi.nlm.nih.gov/pubmed/22561820"
      ]
    },
    {
      "id": "61fa941ec9dfcb9c09000005",
      "type": "yesno",
      "body": "Should Intepirdine be used for Alzheimer's disease?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
          "text": "cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown ",
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1164,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
          "text": "rement after instillation of tropicamide cannot be used as a reliable diagnostic test for Alzheimer's disease. Moreover, test-retest reliability with ",
          "offsetInBeginSection": 1482,
          "offsetInEndSection": 1632,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29212555",
          "text": "BACKGROUND\nIn an effort to intervene earlier in Alzheimer's disease (AD), clinical trials are testing promising candidate therapies in preclinical disease.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
          "text": "It is predicted that some FDA-approved drugs, such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR, could also be used in off-label ways for AD.",
          "offsetInBeginSection": 1829,
          "offsetInEndSection": 2010,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
          "text": "le safety profile similar to placebo.\n\n\nDISCUSSION\nIntepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo",
          "offsetInBeginSection": 969,
          "offsetInEndSection": 1119,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
          "text": "INTRODUCTION\nA previous phase 2b study supported the use of the 5-HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
          "text": "gress in current clinical trials and warrant consideration as emerging treatments for AD. Areas covered: This review discusses 5-HT6 antagonists curre",
          "offsetInBeginSection": 621,
          "offsetInEndSection": 771,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752148",
          "text": "BACKGROUND AND PURPOSE\nTo provide guidance regarding the most appropriate voxel-based morphometry (VBM)-derived method for assessing hippocampal atrophy in early Alzheimer's disease (AD).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 187,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19012869",
          "text": "Thus, rDNA specific methylation pattern could be involved in AD and be used as a marker of the disease or of its progression.",
          "offsetInBeginSection": 336,
          "offsetInEndSection": 461,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
          "text": "Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.",
          "offsetInBeginSection": 1152,
          "offsetInEndSection": 1385,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/9179132",
        "http://www.ncbi.nlm.nih.gov/pubmed/29848076",
        "http://www.ncbi.nlm.nih.gov/pubmed/32321414",
        "http://www.ncbi.nlm.nih.gov/pubmed/21752148",
        "http://www.ncbi.nlm.nih.gov/pubmed/19012869",
        "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34095437",
        "http://www.ncbi.nlm.nih.gov/pubmed/29212555"
      ]
    },
    {
      "id": "6422e2f1690f196b51000043",
      "type": "factoid",
      "body": "What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
          "text": "Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs \u223c30-fold in the clinic (1).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30570431",
          "text": "rotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available",
          "offsetInBeginSection": 453,
          "offsetInEndSection": 603,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30345352",
          "text": " peptide-1 receptor (GLP1R) can productively deliver ASO cargo to pancreatic \u03b2-cells both in vitro and in vivo. Ligand-conjugated ASOs silenced target",
          "offsetInBeginSection": 461,
          "offsetInEndSection": 611,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
          "text": "One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).",
          "offsetInBeginSection": 259,
          "offsetInEndSection": 457,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31099004",
          "text": "Herein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor.",
          "offsetInBeginSection": 189,
          "offsetInEndSection": 340,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15894474",
          "text": "ive vector of antisense oligonucleotide (ASO) and plasmid DNA for the hepatocyte targeting delivery. Gal-LMWC has been successfully prepared and MTT c",
          "offsetInBeginSection": 256,
          "offsetInEndSection": 406,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
          "text": "PA:LFn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 \u00b1 19.1%, 36.4 \u00b1 1.8% and 22.9 \u00b1 6.9% (respectively) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.",
          "offsetInBeginSection": 2003,
          "offsetInEndSection": 2248,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808997",
          "text": "eptor (ASGPR) can serve as potent targeting moieties for hepatocellular carcinoma (HCC) cells. However, efficient targeting to HCC via galactose moiet",
          "offsetInBeginSection": 209,
          "offsetInEndSection": 359,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16686729",
          "text": "SO and chemotherapy or small-interference RNA (siRNA) targeting the clusterin gene was also investigated.\n\n\nRESULTS\nBispecific ASO reduced Bcl-2 and B",
          "offsetInBeginSection": 756,
          "offsetInEndSection": 906,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
          "text": "GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.",
          "offsetInBeginSection": 940,
          "offsetInEndSection": 1106,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24992960",
        "http://www.ncbi.nlm.nih.gov/pubmed/28158620",
        "http://www.ncbi.nlm.nih.gov/pubmed/26546271",
        "http://www.ncbi.nlm.nih.gov/pubmed/16686729",
        "http://www.ncbi.nlm.nih.gov/pubmed/31099004",
        "http://www.ncbi.nlm.nih.gov/pubmed/15894474",
        "http://www.ncbi.nlm.nih.gov/pubmed/30345352",
        "http://www.ncbi.nlm.nih.gov/pubmed/30570431",
        "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
        "http://www.ncbi.nlm.nih.gov/pubmed/29808997"
      ]
    },
    {
      "id": "64299fa957b1c7a315000002",
      "type": "summary",
      "body": "What is rebound COVID-19?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36324801",
          "text": "COVID-19 rebound was defined as documentation of negative then newly-positive SARS-CoV-2 tests.",
          "offsetInBeginSection": 666,
          "offsetInEndSection": 761,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36324801",
          "text": "Previous studies suggest that monoclonal antibodies are an effective outpatient treatment option for patients at high-risk of severe COVID-19, including those with systemic autoimmune rheumatic diseases (SARDs).Nirmatrelvir/ritonavir and molnupiravir are recently-authorized effective oral outpatient SARS-CoV-2 treatment options, but clinical trials were performed among the general population, mostly among unvaccinated and prior to Omicron viral variants.Oral outpatient SARS-CoV-2 treatments may result in COVID-19 rebound, characterized by newly-positive COVID-19 testing and recurrent symptoms, but no studies have investigated rebound prevalence among SARD patients.",
          "offsetInBeginSection": 1973,
          "offsetInEndSection": 2646,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
          "text": "Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
          "text": " infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ",
          "offsetInBeginSection": 72,
          "offsetInEndSection": 222,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
          "text": "o its end, will COVID-19 return again in what is known as a second rebound of the pandemic? In this work, we developed a predictive model that can est",
          "offsetInBeginSection": 444,
          "offsetInEndSection": 594,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Importance\nRecent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 199,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
          "text": "till under global pandemic. China is facing the risks of importation and local rebound of COVID-19. Under the circumstances, preparations for medical ",
          "offsetInBeginSection": 33,
          "offsetInEndSection": 183,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
          "text": "00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\n\n\nResults\nArea-level socio",
          "offsetInBeginSection": 842,
          "offsetInEndSection": 992,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
          "text": "Main Outcomes and Measures\nThree types of COVID-19 rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were examined.",
          "offsetInBeginSection": 1194,
          "offsetInEndSection": 1347,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
          "text": ".1 was the predominant subvariant. The risks of both COVID-19 rebound infections and symptoms 2-8 days after Paxlovid treatment were higher in the BA.",
          "offsetInBeginSection": 959,
          "offsetInEndSection": 1109,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36181334",
        "http://www.ncbi.nlm.nih.gov/pubmed/33132535",
        "http://www.ncbi.nlm.nih.gov/pubmed/35794889",
        "http://www.ncbi.nlm.nih.gov/pubmed/35982673",
        "http://www.ncbi.nlm.nih.gov/pubmed/32388934",
        "http://www.ncbi.nlm.nih.gov/pubmed/35734093",
        "http://www.ncbi.nlm.nih.gov/pubmed/35345769",
        "http://www.ncbi.nlm.nih.gov/pubmed/36324801"
      ]
    },
    {
      "id": "6432fb1957b1c7a31500001e",
      "type": "list",
      "body": "What clinical applications is Zanubrutinib approved for in the United States?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
          "text": "ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i",
          "offsetInBeginSection": 363,
          "offsetInEndSection": 513,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ",
          "offsetInBeginSection": 1223,
          "offsetInEndSection": 1373,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
          "text": "ed accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop ",
          "offsetInBeginSection": 172,
          "offsetInEndSection": 322,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31875923",
          "text": "n's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochr",
          "offsetInBeginSection": 49,
          "offsetInEndSection": 199,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737804",
          "text": "e the turn of the century. The majority of devices have been for cervical arthroplasty. By contrast, biologic devices were most likely to go to panel ",
          "offsetInBeginSection": 1662,
          "offsetInEndSection": 1812,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
          "text": "BTK) approved for the treatment of Waldenstr\u00f6m's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke",
          "offsetInBeginSection": 112,
          "offsetInEndSection": 262,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
          "text": "Zanubrutinib, a second-generation BTK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 118 patients from two multicenter clinical trials, BGB-3111-AU-003 and BGB-3111-206.",
          "offsetInBeginSection": 263,
          "offsetInEndSection": 549,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 543,
          "offsetInEndSection": 890,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
          "text": "Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.",
          "offsetInBeginSection": 1833,
          "offsetInEndSection": 2090,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
          "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.",
          "offsetInBeginSection": 3210,
          "offsetInEndSection": 3439,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35770040",
        "http://www.ncbi.nlm.nih.gov/pubmed/33025948",
        "http://www.ncbi.nlm.nih.gov/pubmed/35651781",
        "http://www.ncbi.nlm.nih.gov/pubmed/33306268",
        "http://www.ncbi.nlm.nih.gov/pubmed/27737804",
        "http://www.ncbi.nlm.nih.gov/pubmed/35950210",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306909",
        "http://www.ncbi.nlm.nih.gov/pubmed/31875923"
      ]
    },
    {
      "id": "61f7cb37882a024a10000029",
      "type": "yesno",
      "body": "Is rilonacept effective for pericarditis?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
          "text": "RHAPSODY (rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1\u03b1 and -\u03b2 cytokine trap) in recurrent pericarditis.",
          "offsetInBeginSection": 143,
          "offsetInEndSection": 383,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
          "text": "-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1\u03b1 and interleukin-1\u03b2 cytokine t",
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35874710",
          "text": "Rilonacept was efficacious and safe for the treatment of CAPS, FMF, recurrent pericarditis, and sJIA.",
          "offsetInBeginSection": 1842,
          "offsetInEndSection": 1943,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24839206",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36398320",
          "text": "It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.",
          "offsetInBeginSection": 780,
          "offsetInEndSection": 884,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18668535",
          "text": "OBJECTIVE\nTo assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 285,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
          "text": "Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.",
          "offsetInBeginSection": 2062,
          "offsetInEndSection": 2162,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
          "text": "rapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.\n\n\nTRIAL REGISTRATION NUMBER\nNCT03737110.",
          "offsetInBeginSection": 1909,
          "offsetInEndSection": 2059,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33882846",
          "text": " and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1\u03b1/IL-1\u03b2 cytokine trap) to treat RP.\n\n\nMETHODS",
          "offsetInBeginSection": 151,
          "offsetInEndSection": 301,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
          "text": "In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.",
          "offsetInBeginSection": 2149,
          "offsetInEndSection": 2353,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33200890",
        "http://www.ncbi.nlm.nih.gov/pubmed/35874710",
        "http://www.ncbi.nlm.nih.gov/pubmed/36316102",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250662",
        "http://www.ncbi.nlm.nih.gov/pubmed/18668535",
        "http://www.ncbi.nlm.nih.gov/pubmed/35350578",
        "http://www.ncbi.nlm.nih.gov/pubmed/23754188",
        "http://www.ncbi.nlm.nih.gov/pubmed/24839206",
        "http://www.ncbi.nlm.nih.gov/pubmed/33882846",
        "http://www.ncbi.nlm.nih.gov/pubmed/36398320"
      ]
    },
    {
      "id": "6413712a201352f04a00003e",
      "type": "list",
      "body": "The 1p19q co-deletion is associated with what types of tumors?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30661193",
          "text": "g prognostic information as well as prediction of treatment response in gliomas. Accurate determination of the IDH mutation status and 1p19q co-deleti",
          "offsetInBeginSection": 91,
          "offsetInEndSection": 241,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
          "text": "INTRODUCTION\nAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
          "text": "Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
          "text": "ty and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative me",
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1106,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
          "text": "In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
          "text": "Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.",
          "offsetInBeginSection": 871,
          "offsetInEndSection": 1110,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
          "text": "We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.",
          "offsetInBeginSection": 1214,
          "offsetInEndSection": 1384,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
          "text": "Of the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion.",
          "offsetInBeginSection": 746,
          "offsetInEndSection": 869,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18416660",
          "text": "ion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular. A further likely prognostic bi",
          "offsetInBeginSection": 513,
          "offsetInEndSection": 663,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28340142",
          "text": "Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.",
          "offsetInBeginSection": 1342,
          "offsetInEndSection": 1558,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33482430",
        "http://www.ncbi.nlm.nih.gov/pubmed/35114775",
        "http://www.ncbi.nlm.nih.gov/pubmed/24197863",
        "http://www.ncbi.nlm.nih.gov/pubmed/19624298",
        "http://www.ncbi.nlm.nih.gov/pubmed/18416660",
        "http://www.ncbi.nlm.nih.gov/pubmed/25971646",
        "http://www.ncbi.nlm.nih.gov/pubmed/34125374",
        "http://www.ncbi.nlm.nih.gov/pubmed/33361717",
        "http://www.ncbi.nlm.nih.gov/pubmed/30661193",
        "http://www.ncbi.nlm.nih.gov/pubmed/28340142"
      ]
    },
    {
      "id": "6429ad3857b1c7a315000003",
      "type": "factoid",
      "body": "The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9601019",
          "text": "ch maps to the X chromosome inactivation centre (Xic) and encodes an untranslated RNA. Truncation of Xist RNA by gene targeting is lethal for female e",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 228,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657585",
          "text": "Xist encodes a noncoding RNA that influences the probability that the cis-linked X chromosome will be silenced.",
          "offsetInBeginSection": 81,
          "offsetInEndSection": 192,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26477563",
          "text": "Thus, the Xist gene carries within its coding sequence an antisense RNA that drives Xist expression.",
          "offsetInBeginSection": 813,
          "offsetInEndSection": 913,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
          "text": "e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c",
          "offsetInBeginSection": 432,
          "offsetInEndSection": 582,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
          "text": "This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.",
          "offsetInBeginSection": 78,
          "offsetInEndSection": 185,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16227973",
          "text": "mes is inactivated in females to enable dosage compensation for X-linked gene products. In rodents and marsupials, only the X chromosome of paternal o",
          "offsetInBeginSection": 37,
          "offsetInEndSection": 187,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
          "text": "ipt (Xist) gene, which is known now to represent the master switch locus regulating X inactivation. In adult cells Xist is transcribed exclusively fro",
          "offsetInBeginSection": 231,
          "offsetInEndSection": 381,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21471966",
          "text": "The developmental regulation of this process has been extensively investigated in mice, where the X chromosome of paternal origin (Xp) is silenced during early embryogenesis owing to imprinted expression of the regulatory RNA, Xist (X-inactive specific transcript).",
          "offsetInBeginSection": 123,
          "offsetInEndSection": 388,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000994",
          "text": "evelopment and is initiated by a unique locus, which produces a long noncoding RNA, Xist. The Xist transcript triggers gene silencing in cis by coatin",
          "offsetInBeginSection": 241,
          "offsetInEndSection": 391,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20950563",
          "text": ", relies on monoallelic activation of the Xist gene. Xist produces a non-coding RNA that can coat the chromosome from which it is transcribed in cis a",
          "offsetInBeginSection": 166,
          "offsetInEndSection": 316,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20950563",
        "http://www.ncbi.nlm.nih.gov/pubmed/9601019",
        "http://www.ncbi.nlm.nih.gov/pubmed/26477563",
        "http://www.ncbi.nlm.nih.gov/pubmed/25000994",
        "http://www.ncbi.nlm.nih.gov/pubmed/16227973",
        "http://www.ncbi.nlm.nih.gov/pubmed/14973270",
        "http://www.ncbi.nlm.nih.gov/pubmed/9487391",
        "http://www.ncbi.nlm.nih.gov/pubmed/20657585",
        "http://www.ncbi.nlm.nih.gov/pubmed/23166390",
        "http://www.ncbi.nlm.nih.gov/pubmed/21471966"
      ]
    },
    {
      "id": "63f92fd033942b094c00000b",
      "type": "summary",
      "body": "What are microexons?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
          "text": "The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
          "text": "Microexons are small sized (\u226451\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
          "text": "However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\u00a0nt, require specialized computational workflows.",
          "offsetInBeginSection": 196,
          "offsetInEndSection": 372,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
          "text": "ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ",
          "offsetInBeginSection": 716,
          "offsetInEndSection": 866,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
          "text": "Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
          "text": "BACKGROUND\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
          "text": "Exons with a length \u2264 30 nt are defined as microexons that are unique in identification.",
          "offsetInBeginSection": 155,
          "offsetInEndSection": 243,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30526869",
          "text": "(2018) uncover novel mechanisms by which the cell regulates splicing of cryptic splice sites and microexons.",
          "offsetInBeginSection": 117,
          "offsetInEndSection": 225,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33378678",
          "text": "Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.",
          "offsetInBeginSection": 936,
          "offsetInEndSection": 1109,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
          "text": "expression or activity of splicing factors (SFs). Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserve",
          "offsetInBeginSection": 73,
          "offsetInEndSection": 223,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34346508",
        "http://www.ncbi.nlm.nih.gov/pubmed/31559909",
        "http://www.ncbi.nlm.nih.gov/pubmed/33859668",
        "http://www.ncbi.nlm.nih.gov/pubmed/34155820",
        "http://www.ncbi.nlm.nih.gov/pubmed/10805741",
        "http://www.ncbi.nlm.nih.gov/pubmed/30526869",
        "http://www.ncbi.nlm.nih.gov/pubmed/33621242",
        "http://www.ncbi.nlm.nih.gov/pubmed/34836511",
        "http://www.ncbi.nlm.nih.gov/pubmed/35895262",
        "http://www.ncbi.nlm.nih.gov/pubmed/33378678"
      ]
    },
    {
      "id": "64041f38201352f04a00001f",
      "type": "yesno",
      "body": "Is tebentafusp effective for uveal melanoma?",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 182,
          "offsetInEndSection": 332,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
          "text": "therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p",
          "offsetInBeginSection": 184,
          "offsetInEndSection": 334,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
          "text": "PURPOSE\nAnti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
          "text": "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33572586",
          "text": "Thus far, no effective methods of pharmacotherapy of this cancer have been found.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 215,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
          "text": "cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors ",
          "offsetInBeginSection": 1143,
          "offsetInEndSection": 1293,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34754859",
          "text": " signs of recurrence at 1 year after surgery.\n\n\nCONCLUSION\nSurgery is an effective treatment for metastatic uveal melanoma. In patients with liver met",
          "offsetInBeginSection": 1100,
          "offsetInEndSection": 1250,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551229",
          "text": "Data showing a proven overall survival benefit with a systemic treatment are lacking.",
          "offsetInBeginSection": 211,
          "offsetInEndSection": 296,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23116575",
          "text": "However, there are still no effective therapies against metastatic uveal melanoma, which is almost always fatal.",
          "offsetInBeginSection": 428,
          "offsetInEndSection": 540,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27183438",
          "text": "n primary malignant intraocular tumor in adults and still lacks effective systemic therapies. Annexin A2 receptor (AXIIR), a receptor for Annexin II, ",
          "offsetInBeginSection": 32,
          "offsetInEndSection": 182,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23116575",
        "http://www.ncbi.nlm.nih.gov/pubmed/27183438",
        "http://www.ncbi.nlm.nih.gov/pubmed/16489097",
        "http://www.ncbi.nlm.nih.gov/pubmed/35716258",
        "http://www.ncbi.nlm.nih.gov/pubmed/33572586",
        "http://www.ncbi.nlm.nih.gov/pubmed/34754859",
        "http://www.ncbi.nlm.nih.gov/pubmed/19032679",
        "http://www.ncbi.nlm.nih.gov/pubmed/35804863",
        "http://www.ncbi.nlm.nih.gov/pubmed/35115315",
        "http://www.ncbi.nlm.nih.gov/pubmed/34551229"
      ]
    },
    {
      "id": "6426bb49690f196b5100004d",
      "type": "summary",
      "body": "What is the Fenton reaction",
      "snippets": [
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26948406",
          "text": "m 5.0 nM to 1.0 \u03bcM with a detection limit of 2.4 nM. Because of the rapid kinetics of Fenton reaction and high specificity for H2O2, the proposed meth",
          "offsetInBeginSection": 1128,
          "offsetInEndSection": 1278,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
          "text": "INTRODUCTION\nFenton reaction is the main source of free radicals in biological systems.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16896806",
          "text": "chelates are formed which inhibit the Fenton reaction owing to a full Fe(II) coordination sphere. In addition to natural nucleotides, we investigated ",
          "offsetInBeginSection": 1200,
          "offsetInEndSection": 1350,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
          "text": "The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradation of biologically and chemically recalcitrant organic compounds in surface waters at circum-neutral pH.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23414832",
          "text": "ium dioxide) and the Fenton reaction exhibited synergistically enhanced hydroxyl (OH) radical generation. Dihydroxybenzoic acid (DHBA) concentration a",
          "offsetInBeginSection": 110,
          "offsetInEndSection": 260,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
          "text": "Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants.",
          "offsetInBeginSection": 134,
          "offsetInEndSection": 234,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
          "text": "Fenton reaction is widely used for hazardous pollutant degradation. Reducing agents (RAs) have been proven to be efficient in promoting the generation",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
          "text": "As anticipated, the Fenton reaction initiates radical formation in all the above targets.",
          "offsetInBeginSection": 761,
          "offsetInEndSection": 850,
          "beginSection": "abstract",
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
          "text": "s that FeII-counteranion complexes are the real catalyst for fast aqueous Fenton reactions. In addition, we found that the Fenton oxidation mediated b",
          "offsetInBeginSection": 708,
          "offsetInEndSection": 858,
          "beginSection": [
            "abstract"
          ],
          "endSection": "abstract"
        },
        {
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494817",
          "text": "Ferroptosis therapy (FT) based on the Fenton reaction of ferrous nanoparticles has been becoming a unique strategy for cancer treatment; however, current ferrous nanoparticles suffer from slower Fenton reaction kinetics, lower ferroptosis efficacy, and long-term toxicity, so it is urgent to construct biocompatible ferrous nanomaterials with highly efficient Fenton reaction activity for cancer FT.",
          "offsetInBeginSection": 0,
          "offsetInEndSection": 399,
          "beginSection": "abstract",
          "endSection": "abstract"
        }
      ],
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19806722",
        "http://www.ncbi.nlm.nih.gov/pubmed/16896806",
        "http://www.ncbi.nlm.nih.gov/pubmed/31476718",
        "http://www.ncbi.nlm.nih.gov/pubmed/10401608",
        "http://www.ncbi.nlm.nih.gov/pubmed/34494817",
        "http://www.ncbi.nlm.nih.gov/pubmed/25496478",
        "http://www.ncbi.nlm.nih.gov/pubmed/17166556",
        "http://www.ncbi.nlm.nih.gov/pubmed/23414832",
        "http://www.ncbi.nlm.nih.gov/pubmed/34190261",
        "http://www.ncbi.nlm.nih.gov/pubmed/26948406"
      ]
    }
  ]
}